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ABSTRACT

Assessing the Proteolytic Virulence Factors of Staphylococcus aureus
Yue Cheng Zhu, 2011
Department of Microbiology and Immunology
University of Western Ontario
Staphylococcus aureus is implicated in many different infections and is known to readily build
biofilms on host tissues and biological implants, leading to numerous transplant and implant
related complications every year. Its proteases, especially those encoded by the sspABC operon,
may play a role in biofilm dispersal and are the focus of this study. A protease-deficient mutant
of S. aureus was constructed through allelic replacement o f the sspABC operon, and the resulting
mutant was used to assess changes in vitro and in vivo through biofilm growth assays under
various conditions of acid stress and carbon source supplementation, and in a murine
bacteraemia model. Deletion of the proteases of sspABC operon led to increased thickness of
biofilm mat and formation of large aggregations of bacterial communities. In the murine abscess
model, deletion of proteases of the sspABC resulted in no significant differences in overall
virulence despite possible differences in bacterial distribution.

Keywords: Staphylococcus aureus, protease-dependent biofilm dispersal, V8 serine protease,
Staphopain B, murine abscess model
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CHAPTER 1: LITERATURE REVIEW
1.1. Significance of Staphylococcus aureus infections - a history
First isolated in the 1880s, Staphylococcus aureus has represented a major source of
morbidity, mortality, and financial burden to society on a world-wide scale (Ogston, 1882). Prior
to the advent of antibiotics for hospital use, most notably penicillin in the 1940s, S. aureus
bacteraemia was associated with poor prognosis and survival of patients, with a reported
mortality rate of over 80% (Skinner and Keefer, 1941). Due to its ability to infect multiple
tissues and utilize multiple points of entry, S. aureus infections manifest in a variety of forms,
the most common of which are skin and soft-tissue infections. The hallmark of such infections is
the pus-filled abscess, forming metastatic lesions in the fonn of boils, carbuncles, and infected
skin vesicles. This mode of infection will be discussed in greater detail in this report. Other
forms of soft-tissue infection include cellulitis and arteriosclerotic gangrene (Skinner and Keefer,
1941). When taken in via the respiratory tract, S. aureus is able to infect and form peritonsillar
abscesses as well as cause otitis media, sinusitis, and more serious conditions such as bacterial
pneumonia. 5. aureus is also implicated in primary osteomyelitis and genito-urinary infections
leading to puerperal sepsis and acute pyelonephritis. As a common cause of nosocomial
endocarditis, cases caused by S. aureus result in higher rates of mortality than other pathogens
(Fernandez-Guerrero et al, 2009). S. aureus produces an array of secreted toxins as well,
including several enterotoxins and toxic shock syndrome toxin, the causative agent of toxic
shock syndrome (Bohach et al, 1990). In conjunction with the wide variety of infectious diseases
associated with S. aureus, it also displays high prevalence in the human population, with an
average rate of 37% asymptomatic carriage of the bacterium in the general population at any
point in time by persistent or transient earners in North America (Kluytmans et al, 1997).
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Carriage of S. aureus has been implicated as a factor that places the carrier at higher risk of
development of infections, most notably in surgical patients, patients undergoing dialysis, and
other immunocompromised individuals (Kluytmans et al, 1997; Noble et al, 1967; Wenzel and
Perl, 1995). Classically, populations at highest risk of S. aureus infections are those associated
with the hospital setting, though community associated strains have been rapidly replacing
hospital associated strains in recent years (Enright et al, 2002). Although treatment regimes have
improved over the past few decades and most S. aureus infections are no longer associated with
high mortality, it remains a leading cause of infectious morbidity in hospitals and the community,
carrying between 2000 and 2001 an estimated annual cost of $14 billion for screening, treatment,
and control in the United States alone (Noskin et al, 2005).

- __

1.2. Description of Staphylococcus aureus
S. aureus belongs to the taxonomic family Micrococcaceae, along with other species of
staphylococci and micrococci (Witte et al, 2006). In appearance, they are Gram positive, nonmotile, spherical cocci that divide along all three perpendicular planes to generate characteristic
irregular grape-like clusters (Ogston, 1882; Tzagalogg and Novick, 1977), for which the genus is
named. The species is named for the golden or orange carotenoid pigment, staphyloxanthin,
which is produced by most strains of the bacteria when they are grown in vitro on plate agar
(Pelz et al, 2005).
As S. aureus represents the most significant human pathogen within the Staphylococcus
genus, several biochemical or metabolic tests have been established for routine use in species
identification. These tests capitalize on the production of coagulase, the activity of which
activates the serine protease precursor prothrombin and results in the formation of a fibrin clot
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(Boden and Flock, 1989), the presence of bacterial cell-surface associated clumping factor, a
protein which will directly bind fibrinogen and cause agglutination in human blood plasma
(McDevitt et al, 1992; Moreillon et al, 1995), and finally the production of the catalase enzyme,
which is produced by all staphylococci and will rapidly decompose hydrogen peroxide to oxygen
and water (Mandell, 1975). Other supplementary selective and differential tests include the use
of mannitol salt agar, the high salt content of which inhibits growth of most bacteria belonging to
genera other than Micrococcaceae, while fermentation of mannitol to acidic fennentation
products that can be observed through an included pH indicator is used for presumptive
identification of S. aureus (Leboffe and Pierce, 2008).

1.3. Commensal colonization
Along with the infections in which it is implicated, S. aureus can also be found
colonizing human hosts without overt detrimental effects (Casewrell and Hill, 1986). It can be
isolated from most areas of the host body, but most commonly in the anterior nares. This is
thought to be the primary reservoir, as elimination of nasally colonized bacteria often results in
elimination of bacteria from other areas of the host. Human hosts colonized by S. aureus can be
divided into three broad groups: persistent carriers, representing 20% of the total population;
intermittent carriers, representing 60% of the population; and the remaining 20% are non-carriers.
Persistent carriers are colonized by and almost always retain the same strain of S. aureus, and
this carriage status appears to offer protection from acquisition of a different strain of S. aureus
when the host is not undergoing antibiotic treatment. This protection is not present in intermittent
carriers, who will be re-colonized by varying strains over time (Noble et al, 1965). Though
colonization is implicated as a risk factor for the development of S. aureus infections, surveys

4

have indicated that there may be no correlation between colonization and serious skin infections
in the community (Miller et al, 2009).
There are multiple factors that influence the likelihood of a human host to be colonized
by S. aureus. Children are more likely to be persistent carriers, and their carrier status often
changes between the ages of 10 and 20. Significantly increased carriage rates are also reported to
occur in hosts with nasal injuries, intravenous drug addictions, S. aureus skin infections, atopic
dermatitis (Breuer et al, 2002), or those with immune-deficiencies such as insulin-dependent
diabetes mellitus, human immunodeficiency virus (HIV) infections, or patients of invasive
procedures such as dialysis (Wenzel and Perl, 1995).
In its primary site of colonization, the nares, S. aureus must be able to adhere tightly to
the surfaces presented. The nostril contains hairs, sebaceous glands, and sweat glands, the
secretions of which possess antimicrobial effects that do not present a barrier to S. aureus
colonization. To adhere, the bacteria may rely on physiochemical forces such as hydrophobic
interactions. Alternatively, the bacteria may bind through the activity of bacterial surface
proteins that interact specifically with host cell receptors (Brouillette et al, 2003; O’Brien et al,
2002). During colonization, toxin production is reduced while surface proteins are upregulated
(Burian et al, 2010). These proteins include adhesins and fibronectin binding proteins, members
of the family of staphylococcal virulence factors named the microbial surface components
recognizing adhesive matrix molecules (MSCRAMMs), which will be discussed in further detail.

1.4. History of antibiotic resistance
Penicillin was introduced for the treatment of S. aureus infections in 1940, and within
two years, a strain of penicillin resistant S. aureus was isolated in a hospital. By 1960, 80% of S.

aureus strains were resistant to penicillin. Currently, fewer than 5% of S. aureus strains remain
sensitive to penicillin (Deurenberg and Stobberingh, 2008; Enright et al, 2002). Methicillin, a
second-generation beta-lactam antibiotic that is resistant to degradation by beta-lactamase
enzyme, was introduced in 1959 for use with penicillin-resistant strains of the bacteria.
Methicillin resistant strains of S. aureus (MRSA) were first isolated in 1961, in which resistance
is conferred by a modified penicillin binding protein encoded by the mecA gene. mecA is located
within a mobile genetic island named the staphylococcal cassette chromosome mee (SCCmec)
thought to originate from the coagulase negative Staphylococcus haemolyticus (Ito et al, 2003).
SCC mec is organized in five domains, beginning with a region of “junkyard" DNA named the J1
region, followed by the mecA gene, the J2 region, the cassette chromosome recombinase (ccr)
gene complex, and finally the J3 region. The “junk” regions appear to exert no effect on
methicillin resistance of the bacteria. There are currently potentially eight allotypes of SCC mec
(Zhang et al, 2009), the majority of which confer only beta-lactam antibiotic resistance, but types
II and III also contain elements that were acquired through horizontal gene transfer and variously
confer resistance to other aminoglycoside, macrolide, and heavy metal antibiotics. The allotypes
are categorized by the type of the two defining ORFs, mec and ccr, the latter of which is
responsible for the mobility of the SCC mec (Hiramatsu et al, 2001; Olivieri et al, 2001; Oliviera
et al, 2002). Currently, the glycopeptide vancomycin is the antibiotic of choice for treatment of
MRSA, though vancomycin intermediate and resistant strains of S. aureus have been isolated in
past years. In S. aureus, vancomycin resistance is acquired through multiple strategies
(Yamakawa et al, 2011), but the most common is through mutation of the vraSR cell wall stress
response system (Belcheva et al, 2011) that results in the accumulation of excess cell wall
peptidoglycan (Cui et al, 2000).
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Strains of MRS A can be further categorized into hospital associated (HA-) and
community associated (CA-), where CA-MRSA are noted for their increased virulence and
ability to infect otherwise healthy individuals. CA-MRSA-10, or USA300 (Miller et al, 2005), is
epidemic within North America and presents the largest challenge to public health, alongside the
CA-MRSA USA400 (McDougal et al, 2003). USA300 is of particular interest due to its
prevalence as an epidemic in the United States, and to its heightened production of virulence
factors (Witte et al, 2007), so much that it is termed a hypervirulent strain (Haque et al, 2007;
Shaw et al, 2004; Gordon and Lowy, 2008). USA300 possesses type IV SCCmec, and in general,
CA-MRSA possess SCC mec types IV or V (Zhang et al, 2008). These are shorter elements, 2428 Kb in size, that do not contain additional antibiotic resistance genes acquired as mobile
genetic elements, whereas HA-MRSA strains often possess SCC mec types II or III (IWG-SCC,
2009).

1.5. The Staphylococcus aureus genome
The S. aureus genome is composed of a circular chromosome of approximately 2.8 Mb in
size, encoding -2900 ORFs, of which 75% represents the core genome. The variability between
strains is attributable mainly to mobile genetic elements including pathogenicity islands,
transposons, bacteriophages, and other insertion sequences (Gillaspy et al, 2006; Malachowa and
Deleo, 2010). These mobile genetic elements include SCCmec, and two elements found
exclusively or first discovered in USA300: staphylococcal pathogenicity island SaPI5, which
encodes two enterotoxin superantigens, and the arginine catabolic mobile element (ACME), a
metabolic element most likely acquired from Staphylococcus epidermidis that contributes to
enhanced ability to survive in hosts (Miragaia et al, 2009).
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Strains will also variously carry extra-chromosomal elements that most commonly confer
resistance to antimicrobial agents. USA300, for example, contains at least one endogenous 27-37
Kb plasmid, pUSA03, which encodes resistance to one or more heavy metals including cadmium
ions (Cd2+), and to various antibiotics including macrolides (erythromycin), lincosamides
(clindamycin), aminoglycosides (kanamycin, neomycin), bacitracin, and others (Diep et al,
2006). Clonal subtypes may also possess smaller plasmids, including pUSAOl, of cryptic
function, and pUSA02, which confers tetracycline resistance and is 99.9% identical to an
antibiotic resistance plasmid found in S. epidermidis (Kennedy et al, 2010).

1.6. Genotyping of Staphylococcus aureus

—_

Outbreaks of S. aureus infections may often coincide with emergence of epidemic clones,
through clonal expansion of pre-existing strains. It is therefore of interest to characterize the
emergent clones in order to differentiate them from non-epidemic strains. There are various
methods of typing S. aureus strains, ranging from phenotypic serotyping for differentiation
through antigen presence, to genetic methods such as DNA fingerprinting through pulse-field gel
electrophoresis (PFGE) (Tenover et al, 1995) and Multilocus Sequence Typing (MLST), the
latter of which has proven to be a preferred method of S. aureus typing due to its unambiguity
(Witte et al, 2006). MLST relies on the analysis of internal fragments of the sequences of seven
housekeeping genes considered to be under neutral selective pressure, and strains are categorized
based on which of multiple possible alleles are present at each of the seven loci. All strains that
differ at no more than two of the seven loci are assigned to a clonal complex that is named based
on the sequence type of the clonal ancestor. Thus. MLST is able to distinguish major clusters of
related lineages in the molecular evolution of S. aureus (Enright et al, 2000).
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MLST is not sufficient for differentiation between strains of a single clonal complex or
analysis of infection outbreaks, in which single nucleotide polymorphisms (SNPs) are more
likely responsible for the emergent variance than allelic recombination. For these purposes, a
method o f typing based on the staphylococcal Protein A {spa) locus of S. aureus was developed
(Koreen et al, 2004. Frenay et al, .1996). The locus contains an “X region” that encodes variable
numbers of 24 bp repeats, of which a number of distinct sequences exist, and the region is prone
to spontaneous mutations as well as gain or loss of repeats through slip-strand mispairing (van
Belkum, 1999). Strains are therefore typed according to the combination of X region repeats they
possess. While this method provides finer discrimination than PFGE or MLST when used to
distinguish members of a single clonal complex, it is unable to distinguish between members of
distinct clonal complexes that possess common X region analyses, and it is a combination of the
three methods that results in the most accurate typing (Strommenger et al, 2006).
Together with SCCmec typing, these molecular typing methods result in a precise and
unambiguous description of extant strains of S. aureus. For example, epidemic strain USA300 is
designated USA300-ST-8-spa-t008-MRSA-IVa, which indicates that it falls under pulse field
pattern USA300, sequence type (ST) 8, and it is a representative member of clonal complex 8
(CC8). It is categorized as spa type t008, and SCC mec type IVa. The other common CA-MRSA
strain in the United States is designated USA400-ST-l-5pa-tl28-MRSA-IVa (Moran et al, 2006;
Zhang et al, 2009) and is a member of CC1. In atopic dermatitis patients, who will commonly be
colonized and infected by S. aureus, CC1 strains have been associated with increased virulence
over strains of other CCs, including CC8 and CC30. CC30 is of interest because it accounts for a
large proportion of nasal carriage (Ko et al, 2008), though this difference is minimal when
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compared to other CCs (Yeung et al, 2010). This provides insight into the evolutionary relations
and epidemiology of important epidemic strains in North America.

1.7. Cell surface virulence
The cell wall of S. aureus is composed of 50% peptidoglycan, which consists of a
polymer of alternating Wacetylmuramic acid (NAM) and iV-acetylglucosamine (NAG)
(Strominger et al, 1959). As with other Gram positive organisms, lipoteichoic acid is a second
major component. Eleven capsular serotypes have been identified, of which type 5 and 8 account
for the majority of MRSA infections and are found to be antiphagocytic (Thakker et al, 1998).
While 90% of clinical isolates are encapsulated, clinical strains either produce microcapsules or,
in the case of the CA-MRSA USA300, no capsule at all (Montgomery et al, 2008). Work with a
capsule-positive strain of S. aureus, Reynolds, has indicated that the presence of the capsule
enhances both nasal colonization (Kiser et al, 1999) in a murine nasal model and reduces
phagocytosis in a murine bacteraemia model (Thakker et al, 1998).
S. aureus produces a variety of cell-surface anchored proteins that allow the bacteria to
bind to components of the host’s extracellular matrix (ECM) using specific binding sites (Walsh
et al, 2008). These proteins, with the exception of an elastin-binding protein (EbpS) (Park et al,
1996; Downer et al, 2001), belong to the MSCRAMM family of virulence factors and are
covalently linked to cell wall peptidoglycan. The MSCRAMM family play important roles in
immune evasion and biofilm formation, as will be discussed in following sections. These
anchored proteins possess a long N-terminal signal peptide required for Sec secretion systemdependent protein secretion and a C-terminal cell-wall spanning domain that contains an LPXTG
motif, a hydrophobic domain, and a tail of positively charged residues. The signal peptide is
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cleaved by a signal peptidase prior to secretion, and the LPXTG motif is cleaved between the
threonine and glycine residues prior to the covalent linkage of the threonine to a side chain of S.
aureus peptidoglycan by the transpeptidase sortase A (Schneewind et al, 1995). Several
MSCRAMMs have been isolated and characterized, including the prototypic representative,
Protein A, first discovered for its ability to bind immunoglobulin G (IgG). Protein A has since
been found to bind von Willebrand factor, a human blood glycoprotein involved in coagulation
(Hartlieb et al, 2000), and so may play a role in mediation of S. aureus attachment to sites of
blood vessel endothelium damage.
Another important class of MSCRAMM is that of the fibronectin binding proteins
(FnBPs). S. aureus produces two related fibronectin binding proteins, FnBPA and FnBPB
(Jonsson et al, 1991), and most strains will express both in tandem. As their name suggests, these
proteins mediate bacterial binding to fibronectin, an ECM glycoprotein that itself binds
components of the ECM and host cell surface integrins to play a large role in cell adhesion and
wound healing. FnBP possesses a ligand binding domain that consists of several repeats
approximately 40 aa in length, and this domain binds to the N-tenninus of fibronectin, which
also consists of a series of repeated motifs (Signas et al, 1989). The presence of the repeats
allows the FnBP to adhere to fibronectin tightly through the construction of a zipper-like
secondary structure that is not apparent in the bacterial protein prior to binding of fibronectin
(Ingham et al, 2004). FnBPA also binds and aggregates platelets, which may result in thrombosis
(Heilmann et al, 2004).
The ability of S', aureus to coagulate blood is due in part to another family of
MSCRAMMs that bind fibrinogen. It currently holds two structurally similar but unrelated
proteins, clumping factor A (ClfA) and B (ClfB), that bind different domains of the host ligand
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fibrinogen in a manner regulated by Ca" concentration. At wound sites, where aggregation of
fibrinogen and platelets would occur, Ca" concentration decreases compared to normal serum
concentrations, thereby de-repressing fibrinogen-Clf interactions and allowing the bacteria to
accumulate at these sites (O’Connell et al, 1998). Virulence was also significantly attenuated in a
septic arthritis mouse model when fibrinogen was depleted prior to infection with ClfAproducing bacteria, indicating that Clf may mediate virulence through other mechanisms as well
(Palmqvist et al, 2004).

1.8. Exotoxins
S. aureus produces a variety of secreted toxins that are responsible for. the majority of its
pathogenesis and the majority of the in vivo phenotypes seen in this study. These toxins fall into
three categories: the membrane active cytolytic toxins, the pyrogenic toxin superantigens, and
the exfoliative toxins (Bohach, 2006; Dinges et al, 2000).
S. aureus cytotoxins include the highly potent a-haemolysin or a-toxin (Hla), which is
secreted as a 293-residue monomer. Once bound to receptor sites, the monomers oligomerize as
either hexamers or heptamers at the cell membrane surface in order to form a ring-shaped pore.
The crystal structure of the pore is mushroom-shaped, and the lower channel is composed of an
anti-parallel (3-barrel that is able to penetrate the cell’s lipid bilayer (Valeva et al, 1996). Upon
formation of the channel, cell death may result directly from loss of osmotic homeostasis, influx
or efflux of cations and other small molecules, necrosis, or apoptosis (Bhakdi and TranumJensen, 1991; Essmann et al, 2003). Indirectly, Hla induces pro-inflammatory cytokines
interleukin-la (IL-la) and IL-6, resulting in vasoaction and other inflammatory effects
(Onogawa, 2006). Hla is responsible for bacterial survival post phagocytosis, and promotion of
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phagocyte lysis and subsequent release of internalized S. aureus (Bramley et al, 1989), a
component of the various methods of immune evasion that will be discussed in further detail.
S. aureus P-toxin is a phospholipase that disrupts cell membranes through the hydrolysis
of sphingomyelin. Uniquely, its action takes place in two stages, the first being sphingomyelin
hydrolysis at physiological temperatures of around 37°C, and the second being physical
disruption of the membrane that takes place at lower temperatures of around 4°C (Aarestrup et al,
2009). While P-toxin is implicated in tissue damage, a-toxin remains the major virulence factor
in infection (O’Callaghan et al, 1997).
Other membrane active exotoxins include 5-toxin, a small helical protein that is thought
to release membrane bound contents of target cells through accumulation of tQxin monomers that
penetrate the membrane (Mellor et al, 1988; Bhakoo et al, 1982). The transcript of this toxin is
involved in temporal control of the S. aureus growth pattern (Somerville et al, 2003), as will be
discussed later. As well, this category includes bi-component toxins, of which y-toxin and
Panton-Valentine Leukocidin (PVL) are the best characterized examples.
These bi-component toxins contain two complementary proteins that act synergistically
to form oligomeric pores (Panton and Valentine, 1932). The two toxin subunits are designated S
and F based on their slow or fast mobility seen in ion-exchange chromatography. PVL is of
particular interest, because while it is not present in the vast majority of clinical isolates, it is
found in many strains of CA-MRSA. PVL is implicated in several of the severe clinical
symptoms of MRS A infections (Boyle-Vavra and Daum, 2007; Genestier et al, 2005), but its
overall role as a determinant of pathogenicity is ambiguous due to conflicting virulence data
(Campo et al, 2011).
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The pyrogenic toxin superantigen set of virulence factors include the staphylococcal
enterotoxins (SEs) and the toxic shock syndrome toxin-1 (TSST-1) (Schlievert et al, 1981).
Superantigens (SAgs) bind to major histocompatibility complex class-II (MHC-II) molecules on
antigen-presenting cells of the host at a distinct region of the molecule that is not responsible for
peptide-antigen binding, and they then interact with and stimulate activation and proliferation of
T-lymphocytes based on recognition of the Vp elements of the T-cell receptor (Jardetsky et al,
1994). This results in non-antigen specific activation of T-cells, allowing up to 30% of the host’s
T-cells to become activated and generating a cytokine storm composed mainly of IL-1, IL-2,
tumour necrosis factor (TNF) a and p, and interferon-y. These and secondary proinflammatory
molecules can result in acute systemic shock, fever, and immunosuppression (Lappin and
Ferguson, 2009). The SEs and not TSST-1 are also implicated in staphylococcal food poisoning,
where they are thought to stimulate mast cells and indirectly affect the emetic reflex centre
(Holmberg and Blake, 1984).
Exfoliative toxins (ETs), o f which there are several forms A to D in S. aureus alone, are
serine proteases that have been found to be the causative agents of staphylococcal scalded-skin
syndrome. The ETs degrade a desmosomal molecule in the skin that mediates cell-to-cell
adhesion, resulting in sterile skin lesions and potential wide-spread peeling of skin strata (Rago
et al, 2000). ETA has also been found to stimulate T-cells with Vp2 chains, much like the
staphylococcal superantigens (Monday et al, 1999).

1.9. Exoenzymes
S. aureus produces a host of extracellular enzymes, most of which comprise direct or
indirect virulence factors. Among these enzymes are proteins also identified as toxins, such as
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the ETs and beta-hemolysin, enzymes important for bacterial metabolism and nutrition, and
enzymes involved in immune evasion or direct virulence through the degradation of host
molecules. The third category overlaps with the fourth, enzymes that specifically mediate
extracellular proteolytic activity and whose attenuation resulted in a decrease in virulence in a
mouse abscess model (Shaw et al, 2004), the staphylococcal proteases. This last category will be
the focus of this work. There are three classes of proteases characterized in S. aureus, the
metalloprotease, the serine protease, and the cysteine or thiol protease. All clinical isolates of S.
aureus encode genes for one metalloprotease, aureolysin, one serine protease, the staphylococcal
serine protease (SspA) or V8 protease, named for the strain in which it was first isolated
(Cannona and Gray, 1987), and two cysteine proteases, staphopain A and staphopain B.
Structural comparisons of staphopains A and B are shown in Fig. 1-A.
These exoenzymes are secreted as inactive zymogens with little or no activity, requiring
proteolytic processing for activation. Staphopain A (ScpA) is encoded in the operon scp AB,
where it is coexpressed with a cognate activation inhibitor, staphostatin A (ScpB). proScpA
possesses a propeptide that immediately follows its N-terminal signal peptide, and the propeptide
domain must be cleaved prior to protease activity. The zymogen rapidly autocatalyzes to release
the propeptide domain in a sequential manner that generates multiple activation intermediates,
cleaving preferentially at sites that possess a bulky or aromatic residue at the P2 subsite, and less
specificity, but often a Thr or Lys at the PI subsite (Kalinska et al, 2011; Nickerson et al, 2010).
While ScpA is secreted, ScpB is a cytoplasmic protein, optimized to capture an
activation/folding intermediate of ScpA (Filipek et al, 2003) by binding in a substrate-like
manner and likely binds to the first intermediate that does not present active site blocking or
hindrance (Nickerson et al, 2010). Like other members of the papain family of proteases, ScpA

Figure 1. Exoenzymes of S. aureus.
A) Structural comparison of staphopain A and staphopain B of S', aureus as shown in ribbon
diagram form. In the left panel, the mature SspB domain is dark blue, and the propeptide is red,
except for the magenta segment spanning the C-terminus of the propeptide, and the catalytic
Cys243 and His34 o are coloured green. The right panel shows a model proScpA structure (ScpA
domain is light blue and the propeptide domain is yellow) superimposed on proSspB, again
shaded in dark blue and red. Image taken from Nickerson et al, 2010.
B) Proteolytic activation steps of the Staphylococcal Proteolytic Cascade are shown. In the
diagrams of aureolysin and SspA, the a helices are shown in red, the p strands in green, and the
loops are in yellow. For aureolysin, the calcium ions are represented by brown spheres and the
zinc ion is represented by a blue sphere. Image compiled from Banbula et al, 1998, and Prasad et
al, 2003.

16

17

displays broad substrate specificity, with high activity against elastin, and is a potent inducer of
vascular leakage through processing of kininogens to release bradykinin (Imamura et al, 2005;
Mattsson et al, 2001), a peptide that functions to induce vasodilation, vascular permeability, and
inflammation upon its binding to epithelial receptors. The remaining proteases of S. aureus are
activated in a step-wise cascade, named the Staphylococcal Proteolytic Cascade (SPC), which
will be discussed in further detail in the next section.
Other S. aureus exoenzymes, responsible for metabolic or pathogenic functions, include
lipase, a term that encompasses both glycerol ester hydrolase, which degrades long chain
insoluble triacylglycerols, and esterases, w'hich degrade short-chain water-soluble glycerol esters.
These lipases are secreted as large proenzymes that possess the same enzymatic activity as the
mature forms (Nokoleit et al, 1995; Rollof and Normark, 1992), and they are thought to possess
a nutritional function, or they may play a role in virulence by releasing long-chain fatty acids that
are known to impair immune function (Rollof et al, 1988). The same long-chain fatty acids are
also bactericidal, and S. aureus is noted for its ability to inactivate these fatty acids through their
esterification to cholesterol and other alcohols. This is accomplished through the action of the
exoenzyme fatty-acid modifying enzyme (FAME), which has been identified phenotypically in
most strains that produce lipase, though the genes encoding the enzyme remain elusive (Kapral
et al, 1992).
In addition to |3-hemolysin, S. aureus produces a second phospholipase C (PLC). PLC
shows phosphatidylinositol specificity and can degrade, in an RNaseA-like manner (Kravchuk
2001), eukaryotic membrane inositol phospholipids that anchor a variety of surface proteins
including receptors and adhesion molecules (Marques et al, 1989). S. aureus also produces two
genetically distinct thermostable nucleases noted for their ability to spontaneously refold after
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thermal unfolding (Tang et al, 2008). The nucleases hydrolyze both single and double stranded
nucleic acids. Lastly, S. aureus produces hyaluronate lyase, a virulence enzyme important for its
ability to hydrolyze hyaluronic acid, a linear polysaccharide and a major structural component of
vertebrate ECM (Makris et al, 2004).

1.10. The Staphylococcal Proteolytic Cascade
The SPC is a stepwise proteolytic activation cascade involved in the activation of three
different proteases of S. aureus, aureolysin, staphylococcal serine protease A (SspA), and
staphopain B (SspB). The SPC is shown in Fig. 1-B. Aureolysin is an M4 class metalloprotease
that requires histidine-mediated coordination of a zinc ion for activity. Like other
metalloproteases such as thermolysin, to which aureolysin is structurally similar, the
staphylococcal enzyme shows broad substrate specificity, preferentially cleaving at sites that
possess a hydrophobic residue at the PI position (Beaufort et al, 2008, Supuran et al, 2002) in
human substrates. Due to its broad specificity, autocatalytic activation of aureolysin is rapid and
occurs at the TL86 and SV90 sites of its N-terminal propeptide (NTP). Like other M4
metalloproteases, the NTP contains a broadly conserved fungalysin-thermolysin-propeptide (FTP)
domain that is crucial for activation, but unlike other metalloproteases, the NTP is not inhibitory,
but serves a stabilization function (Nickerson et al, 2008). Aureolysin is expressed maximally in
mid-exponential growth and has been found to degrade fibrin (Sieprawska-Lupa et al, 2004) and
Cathelicidin LL-37, and conversely is inducible by human antimicrobial peptides (Lai et al,
2007). It inactivates cell surface ClfB of S. aureus (McAleese et al, 2001), and has recently been
characterized as able to degrade complement C3 (Larmaan et al, 2011). Aureolysin is required
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for the activation of mature SspA, where it must remove three final residues of the NTP at the
NV69 processing site in the rate-limiting step.
SspA is encoded by the sspABC operon, in conjunction with SspB and staphostatin B
(SspC). It is a glutamyl endopeptidase that possesses many similarities to trypsin, including the
His-Ser-Asp catalytic triad and the multi-step activation that proceeds through several
intermediates. After its N-terminal signal peptide, SspA possesses a glutamine-rich propeptide
region that is processed autocatalytically at residues Gln43, Gln47, and Gln53, indicating that
secondary structure is present in the zymogen and sufficient for autocatalysis. This self
processing is necessary for optimal processing of the final three-amino acid propeptide region by
aureolysin to release the mature enzyme, which degrades cell surface FnBR (MeGavin et al,
1997) and protein A (Karlsson et al, 2001). The presence of the final three residues completely
blocks function, likely through steric hindrance of the active site (Nickerson et al, 2007). SspA is
necessary for the catalytic activation of SspB, which represents the endpoint of the SPC.
SspB is the second staphopain produced by S. aureus, and like ScpA, it is encoded in an
operon with its cognate inhibitor SspC. The two staphopains have likely evolved through
paralogous ancestry, given their highly similar structures, but SspB possesses much narrower
substrate specificity and has a high preference for Arg in the PI site (Massimi et al, 2002,
Kalinska et al, 2011), such that it will not autocatalytically activate and does not show activity
against elastin fibres. For this reason, SspC is not necessary as an inhibitor, and its mutation is
not deleterious to the bacteria, indicating that it possesses diminished or altered function. The
two staphostatins will not cross-react to inhibit their non-respective staphopains (Filipek et al,
2005).
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SspB distinguishes the pathogenic S. aureus from the commensal S. epidermidis, which
encodes equivalents of aureolysin, staphopain A, and V8 protease, but does not possess
staphopain B. This suggests that the second staphopain arose after evolutionary divergence of the
two closely related species and its contribution is a compelling explanation for the increased
virulence of S. aureus. SspB mimics the activity of plasma serine proteases such as plasmin,
plasminogen activator, and kallikrein by selectively cleaving fibrinogen, fibronectin, and
kininogen, resulting in vasodilation and vascular leakage. Its effects are less dramatic than those
of ScpA, though the two proteases compound to induce a greater effect than either alone. SspB
also possesses potent activity against other components of human ECM including collagen
(Ohbayashi et al, 2010), and chemokines such as chemerin (Kulig et al, 2007).
It is the potential contribution of the SPC as a switch from the colonization mode of
infection to invasive virulence through the previously mentioned degradation of adhesion factors
and host tissues in order to allow metastatic spread, as well as the potential contribution to
biofilm regulation, that will be the focus of this work.

1.11. Immune evasion
Integral to the S. aureus virulence strategy is a multitude of means to evade the innate
immune system, of which a selection will be briefly described.
One of the best characterized immune evasion molecules is the chemotaxis inhibition
protein of staphylococci (CHIPS), which competitively inhibits native agonist binding to the
complement factor C5a receptor and the pathogen associated molecular pattern (PAMP) formyl
peptides receptor (FPR) that neutrophils express (de Haas et al, 2004), thereby preventing
neutrophil localization to the site of infection.
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S. aureus also inhibits the complement system in several other ways, including the highly
effective staphylococcal complement inhibitor (SCIN), which binds to both C4bC2a and C3bBb
C3 convertases to trap them in an inactive state, preventing the activity of C4bC2a mediated
classical and lectin pathways as well as the C3bBb mediated alternative complement pathway
(Garcia et al, 2010). Aureolysin has recently been found to take a more direct approach to
complement inhibition through proteolytic cleavage of C3 (Laarman et al, 2011).
The extracellular adhesion protein (Eap) or MHC analog protein (Map) serves a dual
function, both mediating bacterial attachment to intracellular adhesion molecule 1 (ICAM-1)
expressed on the surfaces of epithelial cells (McGavin et al, 1993), and at the same time
competitively blocking leukocyte localization, which depends upon beta-integrin and urokinase
receptor recognition of the same ICAM-1 ligand (Chavakis et al, 2002. Haggar et al, 2004).
Most clinical isolates of S. aureus produce a bacterial capsule that can also inhibit
opsonisation, but this capsule is minimal or absent in hypervirulent strains, where it is not
necessary in light of other opsonisation inhibition mechanisms, including degradation of C3b and
IgG by plasmin activated by staphylokinase, protein A binding of IgG, inhibition of opsonin
deposition through ClfA mediated coating of bacteria with fibrinogen, and binding of secreted
fibrinogen-binding protein (Clf) to C3 in order to block its deposition on the bacterial cell
surface (Hair et al, 2008).
After S. aureus is phagocytosed, it may survive in or escape the phagolysosome, mainly
through the secretion of the previously described Hla and the various extracellular proteases,
which were found to be rapidly upregulated upon phagosomal uptake (Burlak et al, 2007). Hla
can result in the direct escape of the bacteria from the phagosome through its pore-forming
function, or it may alter the concentration gradient of the phagolysosome, in which acidification
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is a major method of bacterial killing. The proteases have been found to degrade the
antimicrobial peptide (AMP) dermcidin, and may have activity against other AMPs secreted into
the interior of the phagolysosome by granulocytes (Lai et al, 2007). In particular, aureolysin has
been found to cleave the human AMP Cathelicidin LL-37 (Sieprawska-Lupa et. al., 2004). The
muramidase lysozyme produced in phagolysosomes is ineffective against S. aureus due to
acetylation of the bacterial peptidoglycan (Bera et al, 2004). S. aureus also possesses innate
resistance to killing through oxidative burst by the actions of both the superoxide dismutases it
encodes (Karavolos et al, 2003) and its staphyloxanthin pigment, which is able to scavenge free
oxygen radicals (Liu et al, 2005).
As described in the section on exotoxins, S. aureus also produces several toxins that
directly kill leukocytes through the same pore-forming mechanism as haemolytic a-toxin,
including the two component exotoxins PVL and y-toxin.

1.12. Regulation of virulence factors
The success of the S. aureus virulence strategy of rapid switching between colonization
and invasion phases of infection is largely due to tight control of its virulence expression through
several interconnected systems of regulation.
The best characterized system is that of accessory gene regulation (agr), a locus that
encodes both a two component system (TCS) and an effector molecule RNAIII under the control
of distinct P2 and P3 promoters (Recsei et al, 1986). The P2 promoter drives expression of the
agrBDCA operon, where the RNAII transcript encodes the histidine kinase receptor and specific
response regulator of its TCS and its activating ligand, autoinducing peptide (AIP). As a quorum
sensing system, its overall function is to sense bacterial cell density (Novick, 2003). AIP is
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encoded by agrD, and it undergoes post-transiational modification prior to secretion by the
transmembrane AgrB protein. AIP binds to the TCS receptor AgrC on its N-terminal
transmembrane domain, and this induces the activity of response regulator AgrA, which binds to
and upregulates both P2 and P3 promoters in a positive feedback loop. The P3 transcript encodes
8-toxin, but it is the transcript itself that functions as both a translational regulator o f HLA,
which it derepresses, and Protein A, which it inhibits, and as a transcriptional regulator of several
other regulatory systems. The secondary structure of RNAIII is crucial for transcriptional
regulation of exoprotein synthesis that occurs through the action of intermediary regulatory
proteins (Novick et al, 2003), but for its secondary translational activation function, it is likely
that the transcript must unfold in order to allow the conformational change that results in
translation of 5-toxin, and the base-pairing that alters hla mRNA conformation and derepression
(Novick, 2006). Deletions or mutations to RNAIII all alter the expression levels of several
exoproteins (Novick et al, 2003), and a nonsynonymous mutation found in AgrC in the CC30
cluster of strains is associated with its overall decreased virulence compared to its epidemic
ancestor (Deleo et al, 2011). There are four different agr systems, and the presence of specific
systems in MRSA has been correlated with differing sensitivities to vancomycin treatment, but
whether this is a function of the specific agr system or a result of differing genetic backgrounds
is yet to be determined (Seidl et al, 2011).
S. aureus possesses several other known TCSs, including the agr coordinating system
saeRS, and the two agr antagonistic systems arlRS, and srrAB. saeRS upregulates a number of
exoproteins including toxins and adhesive proteins through transcriptional interactions, and it is
induced by the presence of RNAIII but inhibited by acidic pH, hypertonic NaCl concentrations,
and certain antibiotics such as clindamycin, indicating that it functions as a downstream regulator
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heavily influenced by agr that may also add layers of regulation due to environmental factors
(Mainiero et al, 2010; Novick and Jiang, 2003; Rogasch et al, 2006). arlRS activity results in the
down-regulation of various exoproteins, counter to agr activity, and an arlRS mutant shows agr
overexpression, indicating a mutually repressive role (Liang et al, 2005; Fournier et al, 2001;
Fournier and Flooper, 2000). .wAB is inhibited by agr, and it responds to low oxygen stress to
inhibit agr activation and decrease expression of virulence factors in order to lower metabolic
burden and increase bacterial survival, representing a second mutually cross-inhibitory
interaction with agr (Yarwood et al, 2000; Throup et al, 2001).
S. aureus produces a variety of transcription factors including the staphylococcal
accessory regulation (Sar) family of DNA-binding proteins, of which SarA-plays a major role in
regulation of virulence factors due to its interactions with the staphylococcal TCSs, where it
often plays an inhibitory role through the binding of the regulatory element locus (Arvidson and
Tegmark, 2001; Cheung and Zhang, 2002). SarA mutants produce heightened levels of
exoenzymes and exotoxins, and decreased levels of adhesins.
Sar activity is heavily influenced by environmental signals due to its regulation by
alternative sigma factors, of which oB is a major influence on the S. aureus virulon and SarA,
which possesses a c B-dependent promoter. In response to environmental stresses, c Bbinds to
promoter and transcriptional apparatus complexes and alter their stability, leading to
upregulation of many adhesin genes and downregulation of exoproteins and toxins, a is
necessary for transcription of genes involved in response to oxidative stress, including that of the
carotenoid pigment for which S. aureus is named (Novick, 2006; Chan et al, 1998).
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This brief snapshot of S. aureus global regulation shows a portion of the vast
interconnected regulation network in which bacterial virulence factors are controlled by a
combination of multiple levels of cross-inhibition and promotion.

1.13. Abscess model of A. aureus infection
The classical model of S. aureus infection is that of the suppurative abscess, the
developmental phases of which mirror those the bacteria progress through in flask culture growth.
The steps involved in the production cycle of the abscess model and related growth curve and
major protein productions of S. aureus in an idealized flask culture are shown in Fig. 2.
In the initial colonization phase, the bacteria must localize and adhere to a site of
colonization, which is often a wound site, where serum proteins like fibrin or thrombocytes are
acting to form protective or sealing clots, and the previously described MSCRAMMs expressed
on the surface of the bacteria recognize and bind these factors with high efficiency. This
corresponds to the lag and early exponential phases of an in vitro bacterial culture, during which
cell activities such as replication and synthesis of colonization factors are initiated. During this
phase, any glucose available in the media will be fermented, resulting in a drop in the culture pH.
Once the adherent bacteria reach an optimal cell density, as sensed through the quorum
sensing TCS module of the agr system, the activation of transcription of both the P2 and P3
promoters of the agr locus results in a flurry of activity. Through the complex and conditiondependent interactions between the regulatory systems of S. aureus, expression of colonization
factors is downregulated, and secretion of exoproteins, mainly virulence factors such as toxins
and exoenzymes, is initiated. This corresponds to the post-exponential phase of an idealized flask
culture, at which time glucose is depleted and acidity reaches its highest point, saeRS is in

Figure 2. Growth curve and abscess model of S. aureus.
The steps to the formation of a characteristic S. aureus abscess are shown, as well as prototypical
gene products at different stages of the cycle and an idealized growth curve. A schematic
showing major regulatory factors in the growth cycle of the abscess model is included below.
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particular known to be sensitive to a moderate drop in pH, and its inhibition in acidic cultures is
classically associated with a decline in exoprotein synthesis. Its sensitivity to environmental
factors, which overrides the influence that RNAIII exerts, is thought to coordinate with the agr
system and lend an additional level of regulation to the regulatory framework (Novick and Jiang,
2003).
The accumulation of exoenzymes and toxins in the abscess model leads to recruitment of
immune cells, mainly neutrophils, which then surround the bacterial growth to form a
granuloma-like abscess. The neutrophils closest to the bacterial growth will engulf bacteria in an
attempt to kill them prior to their own deaths, resulting in the formation of pus. The infection
may then be resolved by immune system killing of the foreign cells, or the^bacteria may utilize
its secreted proteases and toxins to evade the immune cells, breaking free of the abscess in an
invasive phase of infection and metastasizing to another area of colonization. This expression
and secretion of exoproteins corresponds to stationary phase of a flask culture, during which the
secreted factors play a role in acquisition of nutrients from less ideal sources such as larger
proteins and lipids, which must be broken down, and require metabolic activity on the part of the
bacteria, after which death occurs if no fresh nutrients are available. The glucose initially
metabolized by the bacteria promotes a decreased pH due to the secretion of waste products such
as acetic acid and lactic acid, depending on the aerobic condition of the culture, and the bacteria
will reuptake these waste products to support a second round of growth, or for other purposes
such as the acetylation of the bacterial peptidoglycan, increasing the pH of the culture both
through the removal of the acids and through the secretion of amine wastes (Somerville et al,
2003; Novick, 2006).
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1.14. Significance of staphylococcal biofilms and factors contributing to biofilm production
In addition to the classical abscess model, S. aureus also uses a biofilm mode of growth,
the impact of which has more recently begun to be elucidated. A biofilm is a bacterial
community, mono- or multi-species, that is characterized by increased resistance to antimicrobial,
mechanical, or chemical stresses. Bacteria within the biofilm may have access to decreased
levels of nutrients, slowing its growth and potentially generating highly resistant persister cells
(Singh et al, 2009), while at the same time making the bacteria less sensitive to antimicrobials
that target bacterial metabolic functions or division for their action. To help hold the community
together and act as a physical barrier, the community secretes or builds a biofilm matrix
consisting of variable components. These components consist of various proportions of
polysaccharide (poly-A-acetyl glucosamine; PNAG), bacterial proteins heavily influenced by agr
function and other regulatory networks (Vuong et al, 2000; Lauderdale et al, 2009), extracellular
DNA (eDNA), and possibly some host factors. Surface proteins such as fibronectin-binding
proteins and Protein A are described as important in attachment of bacterial biofilm to growth
surfaces. Many S. aureus biofilms have been found to be susceptible to dispersal by proteases,
indicating a major role of proteins in biofilm matrix formation, which could either be structural
or a method of cross-linking and holding together structural eDNA (Boles and Horswill, 2011).
Due to the reduced environmental stress on biofilm bacteria, S. aureus experience reduced
selective pressure, leading to the generation of genetic variants that may show altered virulence
(Yarwood et al, 2007), a phenotype also induced by detection of mechanical fluid sheer
experienced often by the bacteria in a colonization phase (Castro et al, 2011).
S. aureus virulence may be attributable in part to its ability to form biofilms in infection
settings, and S. aureus biofilms are important in the pathogenesis of infections of biological
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implants, endocarditis, and osteomyelitis. The biofilm bacteria are highly resistant to antibiotic
treatment and the shedding of bacteria into the bloodstream or other systems results in persistent,
recurrent infection that can lead to sepsis, thrombosis, or other blockages. Previous work has
established that in order to produce biofilms, S. aureus must encounter low pH conditions, which
would then repress agr, sae, and sarA function and decrease the secretion of proteases and toxins
(Vuong et al, 2000; Beenken et al, 2003). SspA has been implicated in the dispersal of biofilms
in particular due to its homology with the Esp protease of S. epidermidis, which was found to be
capable of dispersing S. aureus biofilms in co-culture (Iwase et al, 2010). This work will focus
on the effect of deletion of the sspABC operon on the S. aureus biofilm growth phenotype.
The presence of eDNA in the biofilm matrix also indicates that bacterial autolysis is
important for biofilm generation (Rice et al, 2007), and it has been found that this is an important
early step in biofilm formation that allows proper maturation of the bacterial biofilm (Mann et al,
2009). S. aureus autolysis is mediated by at least two autolytic enzymes, the well-characterized
Atl and the more recently discovered Aaa (Heilmann et al, 2005). atl encodes two catalytically
distinct peptidoglycan hydrolases, a A-acetylmuramoyl-L-alanine amidase (AM) and an endo-(3¿V-acetylglucosaminidase (GL) in a large 120kD functional precursor that is processed into the
smaller mature domains (Oshida et al, 1995). Peptidoglycan hydrolases are important for cell
wall turnover, cell separation in division, and potentially play a role in antibiotic resistance
(Sieradzki and Tomasz, 2006; Goessens et al, 1986). This work will concentrate on its role as a
contributor to the biofilm growth phenotype and its potential altered function in the absence of
exoproteases. SspA in particular is implicated, as its inactivation was found to cause pleiotropic
effects including a decrease of atl function (Rice et al, 2001).
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HYPOTHESIS
Past and current research has led to a clearer understanding of the characteristics and
mechanisms available to S. cmreus as a major human pathogen while leaving other questions
unanswered. My hypothesis is that S. aureus encounters host and environmental stresses in
colonization and invasion settings. In particular, decreased pH alters the expression patterns of
the exoproteases of the sspABC operon, which modify the biofilm growth. Elimination of these
proteases will therefore lead to alterations in the biofilm phenotype in terms of biofilm thickness
and matrix cover.
Thus far, detection of protease mediated biofilm dispersal has been done through addition of
exogenous proteases or indirectly through inactivation of broad-acting regulatory systems, so this
work is the first to attempt to show a link between non-polar deletion of proteases encoded by S.
aureus itself and its resultant biofilm growth phenotype.
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CHAPTER 2: MATERIALS AND METHODS
2.1. Growth of strains
Bacterial strains and colonies used in this study are listed in Table 1. S. aureus strains
were maintained in Tryptic Soy Broth (TSB; BD Difco, Franklin Lakes, NJ) media at -80°C in
20% glycerol (Biobasic, Markham, ON). S. aureus were streaked onto TSB or Brain Heart
Infusion (BHI; BD Difco) plates containing 1.5% agar. Cultures were grown overnight in 5 mL
of BHI or TSB in 14 mL culture tubes (VWR, Radnor, PA) at 37°C shaken at 280 rpm before
subculturing into 25 mL of media in 125 mL flasks and shaken at 180 rpm for 6 or 18 hours for
supernatant collection. Media was supplemented with antibiotic as necessary, using kanamycin
(50 pg/mL), neomycin (50 pg/mL), erythromycin (10 pg/mL), tetracycline(2 pg/mL) and
chloramphenicol (10 pg/mL).
For biofilm, zymograms, and assessment of the effect of pH and organic acids on
protease production and activity, CA-MRSA-10 was grown in tryptic soy media made according
to the recipe provided by Becton, Dickinson and Company (1.7% w/v Pancreatic digest of casein
(BD, Franklin Lakes, NJ); 0.3% w/v Papaic digest of soybean (BD); 0.5% w/v Sodium chloride
(EMD, Gibbstown, NJ); 0.25% w/v Dipotassium phosphate, (Sigma Aldrich, St. Louis, MO),
and supplemented with 15 mM Glucose (EMD), 15 mM Acetic acid (EMD), or 15 mM Lactic
acid (Sigma Aldrich) where indicated.
2.2. DNA gel electrophoresis
DNA was suspended in 6x DNA loading buffer diluted to 1x and separated on 0.8%
agarose (Invitrogen) gels containing 0.05% ethidium bromide (EMD) and imaged using the
GelDoc-It® Imaging System (UVP, Upland, CA).
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Table 1. Bacterial strains and recombinant plasmids used in this study
Strains or Plasmid

Description

Source

S. aureus :

Newman sspABCwtc
Newman AaurSspABC
Newman AaurSspABCScpAB
Newman AsarASspABC

Restriction deficient lab strain
s/gB-deficient lab strain; identical to NCTC
8325-4
rfoU-repaired mutant o f RN6390; restored sigB
function; produces robust biofilm
sspABC mutant of RN6390
Complemented sspABC mutant of RN6390
using pRN5548a
sarAw.km mutation in S. aureus Newman;
produces elevated level o f secreted proteases
aurw.LacZ mutation transduced into S. aureus
Newman, confers Erm resistance
sspABCwtc mutation of S. aureus Newman
Double protease deletion of S. aureus Newman
Triple protease mutant of S. aureus Newman
sspABCwtc mutation of S. aureus Newman

USA300 sspABCwtc

sarAw.km
sspABCwtc mutation o f S. aureus CA-MRSA

RN4220
RN6390
SHI 000
RN6390 pMAD wsspABC
RN6390 pRN5528::sspABC
Newman sarAw.km
Newman aurw.LacZ

US A3 00 sspABCwtc
pRN5548 wsspABC
US A3 00 sspABCwtc
pRN5548a
S. aureus

USA300
Complemented sspABC mutant of USA300
using pRN5548a
Complementation vector negative control

Novick, 1991
Peng et al, 1988
Horsburg et al,
2002
This study
Nickerson, 2009
Nickerson, 2009
Nickerson, 2009
This
This
This
This

study
study
study
study

This study
This study
This study

Isolates:

Newman
USA300

Historical ST8 clinical isolate; ca 1952
ST8 community-acquired MRSA

Baba et al, 2008
Li et al, 2009

Promoterless derivative of S. aureus plasmid
pRN5548, which contains the multiple cloning
site of pUC18
Gram-positive allelic replacement vector
pMAD carrying sspABCwtc deletion

Novick, 1991

Plasmids:
pRN5548a

pMAD
pMAD AsspA BC: :tc
pRN5548sspABC
pDG1514

Recombinant pRN5548a carrying sspABC
complementation operon
E. coli plasmid encoding TcR

Arnaud et al, 2004
Passos,
unpublished data
Nickerson, 2009
Guérout-Fleury et
al, 1995
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2.3. Isolation of genomic DNA
S. aureus genomic DNA was isolated using Invitrogen Pure Link1'" Genomic miniprep kits
following a slightly modified manufacturer’s protocol. Up to 2 x 109 cells were harvested via
centrifugation prior to resuspension in 180 pL enzymatic lysis buffer, to which 15 pg/mL of
lysostaphin (Sigma Aldrich) and 100 pg/mL of RNAse A were added. The mixture was
incubated at 37°C for 30 to 60 minutes until turbidity was reduced, when 400 pg/mL of
Proteinase K and 200 pL of Genomic Lysis/Binding buffer (Invitrogen, Burlington, ON) were
added. The mixture was then incubated at 55°C for 30 minutes to complete lysis, which was
followed by the addition of 200 pL of 100% ethanol. The lysate was passed through a
PureLinktm Spin Column to bind through centrifugation, followed by washes with two supplied
Wash Buffers before elution with the supplied Elution Buffer. The eluted product was tested for
purity and DNA concentration using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher,
Wilmington, DE).
2.4. Isolation of plasmid DNA
Plasmid DNA was isolated using the Sigma Aldrich GenElute™ Miniprep Kit according
to the manufacturer’s protocol, slightly modified for S. aureus. 1 mL or less, depending on
cellular density, overnight culture was harvested via centrifugation (all centrifugation steps
occurred at 12 000 g for the isolation of plasmid DNA) for 1 minute before resuspension in 200
pL of provided Resuspension Solution, to which a provided RNAse A solution had been
previously added. For isolation of S. aureus plasmids, 15 pg/mL of lysostaphin (Sigma Aldrich)
was added. The mixture was incubated at 37°C for 30 minutes, after which 200 pL of Lysis
Buffer was added and the mixture was inverted to mix briefly before the addition of
Neutralization Buffer, both provided in the kit. Cellular debris and non-plasmid DNA was
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precipitated through centrifugation for 10 minutes, and the supernatant was transferred to a
GenElute,M Miniprep Binding Column prepared with Column Prep Solution. The plasmid DNA
was bound to the column membrane as the supernatant passed through the membrane during
centrifugation for 1 minute, and the DNA was washed with provided Wash Buffer prior to
elution with provided Elution Buffer. Eluent purity and concentration was determined using a
Nanodrop ND-1000 spectrophotometer (Thermo Fisher).
2.5. Polymerase Chain Reaction, PCR purification, and recombinant techniques
Primers for PCR were designed and ordered from Sigma Aldrich, the full list of which is
in Table 2, and genomic DNA was amplified in 50 pL volumes using 2 ng genomic DNA, 200
pM deoxynucleotide triphosphates (Roche, Laval, QC), 0.3 pM each of forward and reverse
primers, 1x dilution of concentrated PCR reaction buffer containing 1.5 mM MgCb (Roche), and
1.25 U of Taq polymerase (Roche). PCR products were purified using Bio Basic EZ-10 PCR
Products Purification Kit according to the manufacturer’s protocol. The reaction mixture was
mixed with 3 volumes of Binding Buffer 1 provided, and the mixture was transferred to an EZ
IO Spin Column, where it incubated at room temperature for 2 minutes before centrifugation for
2 minutes at 10 000 rpm to bind. The membrane was washed twice with provided Wash Buffer
before elution, after which eluent purity and concentration was determined using a Nanodrop
ND-1000 spectrophotometer (Thermo Fisher).
Enzymatic digests were performed with appropriate buffers diluted to 1x concentrations
and restriction enzymes diluted 1 in 20x (New England Biolabs, Pickering, ON) in volumes of
20 pL. Substrate DNA amounts varied according to isolation eluent concentration. Ligations
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Table 2. Oligonucleotides used for PCR and plasmid modification
Primer

Sequence

Description

dSspABC-Fl

Amplifies 5’ flanking
region of ss/?ABC
operon

dSspABC-F2

CGCGATCCCGGTAAAGGATTTGTAAGGATT
TCC
GCGACGCGTTTGCTGCTGGAGAACTCACAA
GTG
CCCGAATTCCAATTTCTCTACCAGCTCG

dSspABC-B2

GGAAGATCTGTAGGTGAAGACCAAATCCC

Flank_ABC-Fl

TTACCGCTCAACCTGAAGG

Flank_ABC-B2

CATTCTGTTCTGGTGGTGACC

Int_ABC-F2

CATCCACAAC AAACGCAGTC

Int_ABC-B2

GCTCATAAACGATTGGTCGC

aurLacZ-F 1

GCTGTTTTTAAGATTTCAGGAGG

lacZ-Rl

TAACGCCAGGGTTTTCCC

NMN-SepA- FlankFI
NMN-ScpB-FlankB1
NMN-ScpA-Int-Fl

CGTTCTTC ACCTAGCGTTTCAG

NMN-ScpB-Int-B 1

TAGCGTTCCCAACAACTGCC

dSspABC-Bl

Amplifies 3’ flanking
region of j .s/?ABC
operon
.V5/7ABC operon flanking
detection primers

sspABC operon internal
detection primers
—aurwerm internal
detection primers

scpAB operon flanking
detection primers

GGTTATCGTTATATTGCTGCATCAG
CGAGGACAAGAGTGTTCCTACTGAC

scpAB operon internal
detection primers
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were performed with T4 DNA ligase diluted 1 in 20x and T4 ligase buffer (New England
Biolabs) diluted to 1x concentration in a final volume of 20 pL. Ligation substrate amounts
varied according to preparation concentration.
2.6. Bacterial transformation
10 pL volumes of plasmid preparations were electroporated into 80 pL of
electrocompetent S. aureus cells, prepared by growing bacteria in 200 mL of culture to a final
OD of 0.7 before triple-washing with ice cold 0.5M sucrose (EMD) and flash-freezing and
maintenance at -80°C. The mixture was transferred into 2 mm electroporation cuvettes (VWR)
after thawing on ice, and was pulsed under conditions of 100 Q resistance, 25 pF capacitance
and a voltage of 2.5 kV using a Bio-Rad electroporator. 920 pL of TSB was added to the cuvette
immediately after pulsing and inverted to mix, followed by incubation at 37°C before the
mixture was plated on selective and/or differential TSB plates containing X-Gal and/or
antibiotics as necessary and incubated overnight at 37°C or 30°C for amplification of
temperature sensitive pMAD plasmid.
2.7. Construction of mutants
The sspABC operon deletion was generated using the pMAD plasmid vector, into the
multiple cloning site (MCS) of which was inserted S', aureus strain Newman genomic DNA
cloned from the upstream and downstream regions of the sspABC operon, flanking a tetracycline
resistance cassette (TcR). The plasmid construct was first electroporated into strain RN4220,
which will accept foreign DNA, and then moved to RN6390 through plasmid isolation and
electroporation. The strains were maintained at 30°C to allow replication of pMAD from its
temperature sensitive OriTS usable by S. aureus, and successful transformants were identified by
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their resistance to erythromycin (pMAD encoded), tetracycline (TcR encoded), and blue colour
resulting from production of a beta-galactosidase that allowed the bacteria to metabolise X-Gal.
The transformants were then grown at 42°C to eradicate the plasmid and allow the identification
of a double recombination event that replaced the genomic sspABC operon of RN6390 with the
plasmid TcR flanked by genomic flanking regions. The successful recombinants can be
recognized by their white colour on X-Gal, lack of erythromycin resistance, and gain of
tetracycline resistance. The recombinants’ sspABC deletion was then moved to strains Newman,
Newman sarAwkm, Newman aurwLacZ, and USA300 using 085 initially before switching to
®80a phage transduction. Donor strains were grown in TSB with 0.5 mM C aC f before mixture
with the phage vector and plating onto TSB agar containing 2 mM CaCf. Transducing phages
packaged lysed bacterial DNA fragments mistakenly from the donor strain RN6390 sspABCv.tc
and injected the DNA into recipient strains, where a recombination event would replace the
sspABC operon with the TcR at a low rate when the recipient was mixed with transducing lysate
at a MOI of 0.1 or 1.0 before suspension in 1 mL of 0.02 mM sodium citrate. 200 pL of vectorrecipient mixture was then added to 3 mL of phage top agar (0.265 g yeast extract, 0.265 g
casamino acids, 0.578 g NaCl and 0.5 g agar in 100 mL ddLLO) and plated on TSB
supplemented with 4 mM sodium citrate and antibiotic as necessary. Successful allelic
replacement would result in colonies that were resistant to tetracycline, and these transductants
were screened using both PCR and sequencing in and around the locus.
A triple mutant of strain Newman deficient in aur, sspABC, and scpAB encoded proteases
was generated through phage transduction of the scpAB::km deletion into the aurSspABC double
mutant, and the resultant mutant was therefore resistant to tetracycline, erythromycin, and
kanamycin/erythromycin for selection.
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2.8. Complementation of sspABC mutants
Construction of the pRN5548sspA DC plasmid was completed as described for deletion of
the sspABC operon, but using the high copy number pRN5548a plasmid that is maintained stably
in S. aureus and confers plasmid encoded chloramphenicol resistance (Nickerson, 2009). The
plasmid construct was isolated from RN6390 pRN5548s.spAi?C and electroporated into the
sspABC mutant of USA300.
2.9. Protein profiles and Western blotting
Supernatant collected from 25 mL cultures was concentrated using 10% trichloroacetic
acid (TCA; 20% stock) (Alfa Aesar, Ward Hill, MA) precipitation and separated using standard
8% bis-acrylamide gels run at 100 volts for approximately 100 minutes. Protein bands were
visualized with Coomassie stain. Gels for immunoblotting were transferred to FluoroTrans
PVDF membranes (Pall, Port Washington, NY) and incubated with rabbit serum antibody for
SspA for two hours before washing and incubation with IRDye800 linked donkey anti-rabbit IgG
(Rockland Immunochemicals, Gilbertsville, PA). IRDye signal was visualized using the Odyssey
fluorescence scanning system (Li-Cor, Lincoln, Neb.).
2.10. Murine infection model
The murine infection model was performed based on the UWO Animal Care and
Vetinary Services (ACVS) protocol number 2010-211.7 week old female albino Balb/c mice
(Charles River, Wilmington, MA) were housed in UWO ACVS facilities in positive and negative
containment quarters in micro-isolator shoebox colonies. They were challenged with 100 pL of
various strains of S. aureus normalized to 5 x 106 to 1><107 cfu/inoculum, through tail vein
intravenous (IV) injection, and monitored for 96 hours. Early sacrifice occurred under conditions
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of unacceptable distress such as lack of mobility or loss of 25% of initial body mass. After 96
hours, mice were sacrificed through 200 pL 1:1 Euthanyl: H2 O (ACVS; controlled drug license
available) intraperitoneal (IP) injection, and their kidneys, liver, spleen, and heart were harvested
for cfu enumeration post homogenization, or for histopathology processing using a Leica
ASP300 fully enclosed paraffin wax tissue processor (Leica, Concord, ON) followed by Microm
HM335E Microtome sectioning (Leica) and Gram or Hematoxylin and Eosin staining with a
Leica Autostainer XL (Leica). Histopathology processing was performed by UWO Molecular
Pathology core services.
2.11. Biofilm assay
Biofilm assays were preformed in culture treated 96 or 6-well Nunclon Surface plates
(Nunc, Rochester, NY). Biofilm was grown in previously described supplemented Tryptic Soy
media buffered with 0.1M MES buffer (Sigma Aldrich) or 0.1M Bis-Tris buffer (Sigma Aldrich)
to pH 5.5, 6.0. 7.0, or unbuffered. Culture treated Thermanox plastic coverslips (Nunc) were
leaned against the sides of the 6-well plates to provide a surface for biofilm attachment. ~ 5 X
107 bacteria were inoculated into each well of 6 well plates containing 5 mL media and grown
statically at 37°C for 48 hours. The coverslips were then processed for electron microscopy as
previously described (Williams and Bloebaum, 2010). Briefly, coverslips were submersed in
fixative solution containing 2.5% glutaraldehyde (Sigma Aldrich), 0.75% Ruthenium Red
(Sigma Aldrich) in 0.2M cacodylate buffer pH 7.4 (Sigma Aldrich) for 24 hours after an initial
20 min treatment in preincubation buffer of the same formula with 50 mM L-lysine added. The
coverslips were then washed in cacodylate buffer 3X for 10 min, submersed in a 2% solution of
osmium tetroxide (OsCL; Sigma Aldrich) in cacodylate buffer for 2 hours. Coverslips were
washed 3X for 10 min in cacodylate buffer a second time, and finally dehydrated in increasing
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concentrations of ethanol (70%, 95%, 100%) 3x for 20 rain each and desiccated. Biofilm on the
coverslips were coated with gold for imaging at Surface Science Western.
Approximately 2 x 106 bacteria were inoculated into each well of 96 well plates
containing 200 pL media and grown statically at 37°C for 48 hours. 96 well plates were then
washed once with PBS, and biofilm was dried onto the surfaces of the wells. Wells were
incubated at room temperature with 1% crystal violet (Sigma Aldrich) dye for 30 min, washed
with distilled water until wash water ran clear, and remaining crystal violet was extracted with
100% methanol (BD). Extracted dye was diluted as necessary and read at 595mn using a
microplate spectrometer (Bio-Rad, Hercules, Calif.).
2.12. Proteolytic assay
Proteolytic activity assays were performed with supernatant collected from 25 inL
cultures or from biofilm assay plates. Supernatants were normalized to maximum optical density
in 490 uL, completing with sterile Milli-Q H2 O (filtered with Milli-Q system; Millipore,
Billerica, MA), dependent on initial optical density of growth cultures. Mixtures were buffered
using 460 uL proteolytic incubation buffer, which was designed to permit activity of all three
major classes of proteases produced by S. aureus through the supply of necessary co-factors.
Incubation buffer contains 0.02M sodium phosphate (HNa2 PC>4 titrated with H^NaPC^ to pH 7.4;
EMD), 0.15 M sodium chloride (NaCl; EMD), and ImM L-cysteine (Alfa Aesar). 50 uL of 0.2%
w/v FITC-labelled casein (Sigma Aldrich) were added, and the mixture incubated at 37°C in the
dark for 2.5 hours. 200 uL of TCA were used to precipitate remaining undigested casein, and
solubilised FITC was quantified using the Cary Eclipse fluorometer (Varian/Agilent, Palo Alto,
Calif.) at excitation 485nm, emission 535nm.
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2.13. Statistics
Statistical analyses were performed with Graphpad Prism version 5.0c for Mac,
GraphPad Software, San Diego California USA, www.graphpad.com.
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CHAPTER 3: RESULTS
3.1. Deletion of sspABC operon in S. aureus and generation of double and triple protease
mutants
The purpose of this study was to determine the effect that proteases of the sspABC operon
and other major proteases produced by S. aureus exert on its biofilm growth phenotype and
elucidate overall links to virulence. To that end, the sspABC operon of S. aureus RN6390 was
deleted (Fig. 3), and the mutation was then transferred to strains Newman, Newman sarA::km,
Newman aurr.lacZ, and USA300 through phage transduction.
A scpABwkm mutation was transduced into the isogenic mutant of strain Newman lacking
all proteases of the SPC in order to generate a triple protease mutant that lacks all major secreted
proteases with characterized implications in virulence. The Staphopain A knockout was
generated through the same method as the sspABC deletion (Ngai, 2011). The deletion was
verified through PCR using flanking and internal primers NMN-ScpA-Flank-Fl, NMN-ScpBFlank-Bl, and NMN-ScpA-Int-Fl, NMN-ScpB-Int-Bl respectively, and sequencing. Sequences
of primers indicated in this section are shown in Table 2.

3.2. Phenotypic characterization of AsspABC
Secreted proteins of the sspABCv.tc mutant were collected and concentrated through TCA
precipitation for comparison against the protein profile of wild type USA300. Western blot
analysis was also used to phenotypically verify deletion of the sspABC operon through immuno
detection of SspA. Figure 4 shows that no SspA is detectable in the supernatant of USA300
sspABCv.tc when compared to WT USA300. The protein profile shows that other than bands
corresponding to the proteases of the sspABC operon, few other differences in secreted protein

Figure 3. Steps in generating and confirming a deletion of the sspA B C operon.

A) The sspABC operon in wild type Newman and the binding locations of primers
dSspABC_Fl, dSspABC_Bl, dSspABC_F2, and dSspABC_B2, which were used to
clone the 5' and 3' flanking regions of the sspABC operon. Primers and sequences are
listed in Table 2.
B) DNA electrophoresis gel of PCR products using flanking and internal detection
primers Flank_ABC_Fl, F l a n k A B C B l , and Int_ABC_F2, Int_ABC_B2 respectively.
Lane 1 shows USA300 wild type genomic DNA amplified with internal detection primers
annealing within the sspABC operon. Lane 2 shows no product using the same primers in
the USA300 sspABC. :tc mutant. Lanes 3 and 4 show wild type and mutant genomic DNA
amplified using external primers, generating products that differ in size by 0.5 Kb,
corresponding to the difference in size between the sspABC operon and the smaller TcR
cassette.
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Figure 4. Protein profile and SspA immunoblot of USA300 and isogenetic variants.
Supernatants of USA300, USA300 sspABCv.tc, USA300 sspABCv.tc p R N 5 5 4 8 ::s^ 5 C , and
USA300 sspABCv.tc pRN5548a were collected and analyzed for protein expression through
coomassie staining and immunoblotting. Arrows point to the locations of mature SspA and SspB
in USA300. The SspA immunoblot shows SspA secretion in USA300 wild type and the
complemented mutant USA300 sspABCv.tc pR N 5548::.«^5C, but not in the sspABC mutant or
mutant with pRN5548a plasmid alone.
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expression exist, indicating that deletion of the operon has not caused any adventitious
pleiotropic effects. The expression profile shows the absence of the various protease activation
intermediates as well as a few secreted proteins processed by proteases of the sspABC operon in
the deletion mutant. The sspABC deletion was complemented in trans through expression of the
operon on high copy number plasmid pRN5548a, and as seen in the protein profile and Western
blot, overexpression of proteases occurred, whereas complementing with pRN5548a alone did
not restore SspA production when moved into the mutant as a control.
Mass spectrometry, to assess and identify differences in secreted protein profile, was also
performed on 6 and 18 hour supernatants of USA300 WT and AsspABC mutant, as well lab
strain SHI000, which is a derivative of NTC 8325-4 that has been repairedior a function and
produces low secreted protease levels and robust biofilm growth. SHI000 is included in this and
following results as a control for low protease production and high biofilm growth, both areas in
which it behaves significantly different compared to USA300. Other than differences in protease
expression, USA300 sspABCv.tc showed higher levels o f autolysin precursor in 6 h supernatant
compared to wild type. Another band of approximately 30 kD was upregulated in the protease
mutant of USA300 but could not be identified via mass spectrometiy. Figure 5 shows protein
bands of interest and their identities, while the corresponding accession numbers and percent
confidence values are displayed in Table 3.

3.3. USA300 produces elevated levels of exoprotease but not exotoxin in media buffered to
pH 5.5 and 6.0 in the presence of glucose
Glucose is the primary and preferred carbon source used by S. aureus, and it has been
found to be necessary for biofilm formation. The classical model states that as glucose is

Figure 5. Identification of secreted proteins of USA300, USA300 sspA B C ::tc, and SH1000.
Protein profile of culture supernatants of USA300, USA300 sspABCv.tc, and SH1000 grown in
unbuffered TSBG for 6 or 18 hours. Bands identified by mass spectrometry: 1) lipase, 2) SspA, 3)
LukF, 4) Autolysin precursor, 5) Hla, autolysin (glucosaminidase domain), 6) LukS, 7) autolysin
(amidase domain), SspB, 8) unidentifiable.
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Table 3. Name, confidence score, and accession number(s) of secreted proteins identified by
mass spectrometry.

#

Protein

Confidence Score
C.I.%

Protein Database
Accession #

l

Lipase

100

57651062

2

SspA

100

15924038

3

LukF

100

9635192

4

Autolysin precursor

100

49483217,21282665

5

Hla

100

15924153

Autolysin (GL)

100

32968086, 2506027

6

LukS

100

21283108

7

Autolysin (AM)

96.671

49483217, 15926639

SspB

97.8

15924037,21282660,
57650241

8

No results
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fermented, the decrease in pH caused by accumulation of fermentation products inhibits agr
activity, resulting in decreased levels of ogr-regulated toxins and enzymes, including proteases
that would otherwise disperse the biofilm growth. According to this model, growth of S. aureus
in glucose or in decreased pH conditions would therefore result in lowered production of
proteases. pH is most commonly adjusted to 5.5 in the literature to represent acidity conditions
encountered by colonizing bacteria on human skin. In contrast, as seen in Figure 6 , SspA
protease production was dependent on the presence of glucose. More protease is detectable at 6 h
growth in the various media than at 18 h growth, and the most SspA is detectable in media
buffered to pH 5.5. The intensity of the SspA bands decrease as the pH of the media increases.
There is also a reduction in the amount of SspA protein at 18 h, likely due to instability of the
SspA protease. Table 4 lists the pHs measured before, during, and after growth of USA300 in
buffered and unbuffered TSB.
Alpha toxin (Hla) production was also assayed under these pH conditions. Although Hla
is under the control of the agr locus similarly to SspA, it is translationally de-repressed by
RNAIII in a more direct mechanism of regulation, and the condition in which the most SspA was
produced (pH 5.5) corresponded with the condition in which Hla production was dramatically
decreased. This suggests additional sources of regulation that layer upon ngv-based
transcriptional regulation of SspA. The proteases may also play a role in the degradation of Hla
in culture supernatant.

Figure 6. Immunoblots for detection of SspA or Hla toxin in culture supernatant of
USA300.
Cultures were grown for either 6 h or 18 h in TSB or TSB containing 15 mM glucose. The TSBg
was buffered with MES at pH 5.5, or Bis-Tris at pH 6.0 and pH 7.0 as indicated.
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Table 4. pH and growth data of USA300 in chemically-defined media containing glucose,
acetic acid or lactic acid in buffered and unbuffered media.
pHi

pHm

pH,

OD600i

OD600,

TSBg

7.05

6 .0 2

7.85

0 .1

9.02

TSBg 0.1 M MES pH 5.5

5.48

5.45

5.92

0.1

5.72

TSB 15 mM acetic acid

6 .6 8

5.44

7.96

0.1

4.56

TSB 15 mM acetic acid
0.1 M MES pH 5.5

5.45

5.38

5.87

0.1

2 .6 6

TSB 15 mM lactic acid

6.81

5.96

8.32

0.1

6.04

TSB 15 mM lactic acid 0.1
M MES pH 5.5

5.52

5.43

5.75

0 .1

4.15

* pH was measured initially and at
initially and 18 hours.

6

(mid), and 18 (final) hours, while OD600 was measured
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3.4. Increase in SspA levels of USA300 corresponds to increased overall proteolytic activity
As shown in Figure 6 , optimal SspA production occurred at acidic pH, and was also
dependent on glucose as a substrate. To determine how protease activity was influenced by this
variation in SspA production, the same culture supernatants were assayed for total protease
activity using FITC casein as a substrate (Fig. 7). At 18h of growth, protease activity of USA300
grown in unbuffered TSBg was significantly greater compared to culture grown in TSB alone,
confirming that glucose is needed for optimal protease production. Moreover, the protease
activity of US A3 00 grown in TSBg pH 5.5 was significantly greater than culture grown in TSBg
pH 7.0. In addition, when grown in TSBg pH 5.5, the protease activity of USA300 sspABCv.tc
was nearly 3-fold less than wild type USA300, confirming a major contribution of SspA and
SspB. Protease activity was also compared to S. aureus strain SHI 000, which produces robust
biofilm, and in previous work was used to assess the influence of secreted proteases on biofilm
production. The data reveal that SH I000 had negligible protease activity, being far less than that
of protease deficient mutant USA300 sspABCv.tc.
In contrast to the 18h cultures, protease activity at 6 h was much lower despite maximal
SspA immunoblot detection occurring at the earlier time point, indicating that SspA was likely
detected in an inactive form. The proteolytic activity that does occur shows a trend of increasing
as the pH of the culture medium was increased from 5.5 to 7.0. This may reflect the activity of
the metalloprotease Aureolysin, which is produced in mature form prior to the appearance of the
SspA and SspB precursors, and is susceptible to rapid autocatalytic degradation beyond 6 h of
growth (Nickerson et al, 2008).

Figure 7. Proteolytic activity of USA300 and USA300 sspABCr.tc grown under various pH
conditions.
18h cultures of USA300 and its sspABCv.tc mutant were grown in TSB with or without glucose
supplementation and buffered to different pHs. SHI000 is included as a control showing low
protease activity. ** p<0 . 0 0 1
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3.5. Effect of other carbon sources on SspA production
Although our data reveal that glucose promotes optimal production of secreted protease,
another tenet of the biofilm model is that acidic end products of glucose fermentation, acetic and
lactic acid, are metabolized on depletion of glucose to promote additional growth. Acetic acid
also has an important role in biofilm development by promoting expression of autolytic activity,
which is required for release of eDNA, a structural component of biofilm matrix (Rice et al,
2007). It is therefore of interest to evaluate the influence of acetic acid and lactic acid production
of SspA.
As seen in Figure 8 , compared to TSB alone, medium supplemented with 5 mM acetic
acid promoted a slight stimulation in production of SspA, an effect that appeared to diminish at
10 mM acetic acid. In a separate experiment when TSBg buffered to pH 5.5 was supplemented
with acetic acid, SspA production decreased in a dose-dependent manner and was abrogated at
20 mM acetic acid. Supplementation of glucose-free media with acetic acid resulted in a
dramatic decrease in final cell density (less than half of final OD of S. aureus grown in TSBg,
Table 4) at 18h, while this was not observed with lactic acid.
Conversely, Figure 9 shows that addition of lactic acid to TSB results in increased
production of SspA. These data suggest that while lactic acid is imported and utilized as a carbon
source, acetic acid inhibits growth, and results in lower SspA production, possibly as a result of
the growth inhibition. It is therefore likely that acetic acid is not used as a carbon source.
Supplementation with neither organic acid resulted in similarly high levels of SspA production
compared to those facilitated by glucose supplementation, so acetic acid and lactic acid were not
used in further experiments designed to elucidate the effect of proteases on various growth
phenotypes.

Figure 8. The effect of acetic acid supplementation on protease production levels.
A) Unbuffered TSB made without glucose was supplemented with increasing

concentrations of acetic acid.
B) Increasing concentrations of acetic acid in buffered tryptic soy media made with

glucose show a dose-dependent decrease in protease production.
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Figure 9. The effect of lactic acid supplementation on protease production levels.
Unbuffered TSB made without glucose was supplemented with increasing concentrations of
lactic acid. Arrows point to the likely ran distance of SspA.
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3.6. The sspABCr.tc mutant of USA300 produces significantly more biofilm than wild type
USA300
The classical model of S. aureus biofilm growth states that glucose supplementation of
growth media is necessary for biofilm growth and maturation, as metabolism of glucose results
in the decrease in pH that inhibits agr-regulated exoproteases, including SspA (Boles and
Horswill, 2008; Somerville et al, 2003). However, having ascertained that media buffered to an
acidic pH corresponds to increased protease production and activity, the effect of glucose
supplementation and buffering of media to various pHs on the biofilm growth phenotype was
then examined. In a microtitre plate biofilm assay (Fig. 10), USA300 and USA300 sspABCv.tc
were grown in TSBg and buffered to different pHs. In all pHs, the sspA BC:'Jc mutant produced
significantly more biofilm than the wild type (** = p<0.001). Unbuffered TSBg supported less
biofilm growth than unbuffered TSB that lacked glucose, which supports the claim that proteases
are responsible for the dispersal of biofilm, since supplementation with glucose promotes
increased protease expression and activity. The highest levels of biofilm growth occurred in
TSBg and buffered at a pH of 5.5 or 6.0, conditions which, counter-intuitively, also resulted in
the highest proteolytic activity.

3.7. High biofilm production is correlated with low proteolytic activity
Though low pH is correlated with high protease production and proteolytic activity in
flask cultures, this is not necessarily representative of proteolytic activity in the biofilm growth
mode. S. aureus is known to differentially express many different gene products in its biofilm
phenotype compared to planktonic growth. In order to determine the amount of proteolytic
activity displayed by S. aureus during biofilm growth, USA300 and USA300 sspABCv.tc were

Figure 10. Microtitre plate biofilm assay of SH1000, USA300, and USA300 sspA B C r.tc.
Strains were grown in buffered or unbuffered TSB or TSBg as indicated. After 48h growth,
biofilm was quantified by staining with crystal violet (A 595 ). Strain SHI000 is included in
unbuffered TSBg and TSBg buffered to pH5.5 as a positive control known to produce robust
biofilm. ** p<0 .0 0 1 .
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grown in a microtitre plate biofilm assay in TSBg and buffered to different pHs. Supernatant was
collected from each of the microplate wells, pooled, and assayed for proteolytic activity. As seen
in the representative trial presented in Figure 11, the amount of proteolytic activity is negatively
correlated with robustness of biofilm growth. In this trial, when biofdms were grown in TSBg
buffered to pH 6.0, USA300 showed anomalously low proteolytic activity, but the data is
included to emphasize that when there was no difference in proteolytic activity, there was also no
significant difference between biofilm growth of the wild type compared to the mutant.
Compared to the amount of proteolytic activity exhibited by supernatant collected from flask
cultures (Fig. 7), the supernatant collected from biofilm growth showed lower overall proteolytic
activity despite the increased amount of time in which the biofilm was allowed to develop. The
proteases produced by the biofilm bacteria may have degraded before the proteolytic assay was
performed due to the long length of time, or the biofilm communities may be producing lower
levels of proteases altogether. Due to the static nature of the biofilm, any secreted products may
be captured within the matrix of the biofilm and thereby concentrated, allowing even a small
amount of secreted proteins to cause a significant effect. All differences are significant to a pvalue of less than 0 .0 0 1 . (** = p< 0 .0 0 1 )
3.8. USA300 sspABCr.tc shows a different qualitative biofilm growth phenotype
In addition to producing more quantifiable biofilm adherent to the bottom and walls of
serum-coated wells in microtitre plate assays, the sspABCwtc mutant of USA300 produces
clumps of bacteria visible to the naked eye. As seen in Figure 12, SH1000, a known robust
biofilm maker, tends to produce a uniform biofilm in a thick mat without any visible adherent
clumps. USA300 produces very little visible biofilm, as does USA300 sspABCwtc complemented

Figure 11. Correlation between biofilm growth and proteolytic activity.
Biofilm assay supernatant was collected and pooled from a microtitre plate biofilm assay in
which USA300 and USA300 sspABCv.tc were grown in TSBg buffered or unbuffered to various
pHs. The top panel shows biofilm production in the various growth conditions, and the bottom
panel shows the proteolytic activity of the supernatant collected from the microtitre plate wells in
which the biofilms grew for 48 h. Soluble FITC was included in 0.1 and 0.25 pg amounts as
standards. ** = p<0 .0 0 1 :
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Figure 12. Physical characteristics of biofilm grown in microtitre plate wells.
Biofilm of each strain were generated in rows of 12 duplicate microtitre plate wells coated with 1%
human serum in PBS and grown in TSBG buffered to pH 5.5 with 0.1M MES. An uninoculated
blank row of wells is shown below biofilm rows.

71

SH1000

USA 300

USA 300
A ss p A B C

U S A 3 0 0 A ss p A B C
p RN 5 548ssp A ßC
U S A 3 0 0 A ssp A B C
PR N 5548

blank

72

in trans with pRN5548::sspABC, whereas USA300 sspABCv.tc and USA300 sspABCv.tc
containing only pRN5548 both produce comparable biofilm density and clumping.

3.9. Scanning electron microscopy of biofilm growth phenotype
Further detail on the phenotypic differences between the biofilm growth modes of
USA300 wild type and protease-null mutants was elucidated through preparation of biofilm on
serum coated plastic coverslips half-submerged in TSBg pH 5.5. Biofilm was found to grow in
distinct zones of thickness, so the cover slips were trimmed after growth to isolate areas of true
biofilm growth located between the tide line, which represents the liquid/air interface at which
point debris and bacteria will adhere to the cover slip due to evaporation of media, and the thick
growth at the bottom of the cover slip, which represents bacteria that had settled through
sedimentation. Scanning electron micrographs of US A3 00 biofilm display adherence and growth
that most typically appeared as a thin monolayer covered with biofilm matrix, though there were
also areas in which the bacteria formed thicker, clumped growth that was not covered with
matrix, suggesting that the bacteria had burst free of the matrix cover and grown upwards when
uncovered (Fig. 13-A). In other areas of biofilm growth, a thicker, uniform mat of bio film had
developed that was covered with a layer of matrix material, as shown in the cross-sectional
image in Figure 13-B. The cross-section of this mat was measured to be approximately 5.5 pm
thick.
As seen in Figure 14, USA300 sspABCv.tc grows thicker biofilm in which growth is
consistently covered with at least some biofilm matrix. The matrix appears to coat the top surface
of the biofilm but does not appear throughout the bacterial cells packed into the biofilm mat,
which reaches 17.5 pm in thickness (Fig. 14-B). The micrographs show flat regions of biofilm

Figure 13. Scanning electron micrographs of USA300 biofilm.
Top view (A) and cross section (B) images were taken of USA300 biofilm grown on a plastic
cover slip coated with human serum and grown in TSBG buffered to pH 5.5. Biofilm mat was
measured to be 5.5 pm in height.
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Figure 14. Scanning electron micrographs of USA300 sspAB C::tc biofilm.
Top (A, C) and cross section (B, D) views were taken of USA300 AsspABC biofilm grown on a
plastic cover slip coated with human serum and grown in TSBG buffered to pH 5.5. The upper
panels show representative thick biofilm growth with areas of mat reaching 17.5 pm in height.
The lower panels show one of the adherent clumps noticeable in microtitre plate biofilm as a
towering biofilm community filled with bacteria and measuring 50 pm in height.

76

77

growth separated by zones containing only sparsely distributed single cells scattered on the
growth surface, but the shapes of the flat regions suggest that they were initially components of a
single thick, uniform mat that had cracked and split into the pieces visible in microscopy due to
the desiccation process during preparation of the biofilm for microscopy (Fig. 14-A). The
biofilm formed by the protease mutant was most likely continuous, thick mat, unlike that of
USA300 wild type, which had zones of mat interspersed with zones of near monolayer growth
(Fig. 13-A). The large clumps of bacteria that had been visible to the naked eye in the microtitre
plate biofilm assays are massive communities of bacteria that tower to heights of 50 or more pm
(Fig. 14-C and D). There seems to be a link between loss of proteolytic activity and thickness of
biofilm growth, and the massive bacterial communities seen in the protease-null mutant are
likely the result of decreased rate of biofilm dispersal or degradation of structural materials.

3.10. Deletion of the sspABC operon in USA300 produces no overall change in virulence in
a mouse infection model
The differences established between wild type and protease-deficient mutant in the
biofilm model of growth may reflect changes in the other major mode of colonization and
infection S. aureus utilizes: the abscess model. S. aureus is heavily associated with various
abscess-based infections, and US A3 00 is most often found in the community in the form of
suppurative abscesses and other soft-tissue infections. Its more serious forms of infection are
often the result of abscess formation within internal organs, including acute pyelonephritis, an
inflammation of the kidney. For these forms of infections, a mouse bacteraemia model was used,
in which the mice were challenged with wild type and protease-null mutants in order to
determine the effect of protease mutations on the organ abscess mode of infection following
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challenge via bacteraemia. S. aureus was normalized to a challenge inoculum of approximately 5
x 106 CFU/dose and introduced to Balb/c albino mice through tail vein injection. S. aureus will
then pass through and colonize the kidney first, be carried by the bloodstream to the heart, from
where it will spread to various other organs. This model generates an acute systemic infection in
which the mice are sacrificed after a 96 hour incubation period or when the mice are deemed too
sick before the incubation period has elapsed, and its kidneys, liver, spleen, and heart are
harvested and the bacterial load in each organ is enumerated in terms of CFU/organ. Figures 15
to 17 show the pooled results of several mouse bacteraemia challenges using strains Newman,
USA300, USA300 sspABCwtc, and USA300 sspABCwtc pRN5548.s-.s-p.4i5C. Figure 15 shows
bacterial load in kidneys and spleen, in which there was no significant difference between
US A3 00 and its isogenic variants, although there was a slight, nonsignificant trend toward
increased bacterial load in the kidney in mice challenged with USA300 sspABCwtc as compared
to USA300 wild type. Figure 16 shows bacterial load in the liver and heart, where there is a
small but significant difference in liver bacterial load between USA300 sspABCwtc and USA300
sspABC::tc pRN5548::sspA BC. In general, strain Newman was recovered from mouse organs in
greater number, with significant differences in the liver, spleen, and heart. Strain Newman
exhibits very low proteolytic activity due to an SNP in its saeRS locus that results in increased
production of colonization factors and decreased production of exoenzymes and exotoxins. This
may result in better adherence and evasion of the immune system because of the decreased
amount of inflammatory virulence factors. Newman is noted to produce large abscesses in mouse
kidneys. There were no overall significant differences in virulence measured through weight loss
of the challenged mice, as seen in Figure 17.

Figure 15. Infection of kidney and spleen by S. aureus USA300 and variants.
Organ CFU counts comparing strains Newman, USA300, USA300 sspABCwtc, and USA300
sspABCv.tc pRN5548::sspABC. These are pooled results from several trials, so N varies from
strain to strain and are as follows: Newman 30, USA300 18, USA300 sspABCwtc 20, USA300
sspABCwtc pRN5548::55/7^45C 3. ** p<0.001
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Figure 16. Infection of liver and heart by S. aureus USA300 and variants.
Organ CFU counts comparing strains Newman, USA300, USA300 sspABCwtc, and USA300
sspABCv.tc p R N 5 5 4 8 : . 8 C . These are pooled results from several trials, so N varies from
strain to strain and are as follows: Newman 30, USA300 18, USA300 sspABCv.tc 20, USA300
sspABC'.:tc p R N 5 5 4 8 3. * p<0.05 ** p<0.001
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Figure 17. Weight loss in mice challenged with S. aureus.
Organ CFU counts comparing strains Newman, USA300, USA300 sspABCv.tc, and USA300
sspABCv.tc pRN5548: .sspABC. These are pooled results from several trials, so N varies from
strain to strain and are as follows: Newman 30, USA300 18, USA300 sspABCv.tc 20, USA300
sspABCv.tc PRN5548::ss/?vi5C 3.
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3.11. Deletion of subsequent exoproteases in strain Newman produced no overall change in
virulence in a mouse infection model
As USA300 presents difficulties in the construction of multiple deletions due to its innate
resistance to many of the common antibiotic selection markers, double and triple protease
mutants were constructed in strain Newman, which is also a member of ST-8, and so is
genetically similar to USA300. As shown in Figures 18 and 19, no overall difference in virulence
as seen in the weight loss of the challenged mice was detected, and as described in the previous
section, Newman and all its derivatives produce higher CFU per organ rates than USA300, likely
due to its production of excess colonization factors and decreased toxin and protease output. A
mutant of Newman deficient in action of the sarA transcriptional regulator was included as a
control showing the effect of challenging mice with a variant known to display elevated protease
and toxin production. The sarA mutant had significantly lower CFU per organ counts than other
variants of Newman, indicating that this experimental protocol is sufficient for detection of
phenotypic differences resulting from pleiotropic alterations to secreted protein levels. Figure 18
shows the double protease deletion of Newman generated a higher CFU/organ count in the
spleen, but this difference was very slight and on the cusp of significance. The triple protease
mutant produced lower CFU/organ counts in the spleen than the double mutant despite
possessing the same deletion of all proteases of the SPC, suggesting that although a mutant
deficient in SPC proteases was able to better colonize mouse kidneys, the lack of all major
secreted proteases was perhaps detrimental to the ability of the bacteria to colonize. The increase
in CFU/organ count was also present in the heart, as seen in Figure 19. The presence of two
organs in which there was a significant increase in CFU load in mice infected with a mutant
deficient in all proteases of the SPC suggests that the proteases may have an effect on

Figure 18. Infection of kidney and spleen by S. aureus Newman and variants.
Organ CFU counts comparing strain Newman with its single, double, and triple mutants. These
are pooled results from several trials, so N varies from strain to strain and are as follows:
Newman 30, Newman sspABCwtc 20, Newman aur::LacZ 20, Newman ÀaurSspABC 17,
Newman àaurSspABCScpAB 10, Newman sarAv.km 10, Newman AsarAsspABC 10.
* p<0.05 ** p<0.001

S p le e n

log cfu/organ

a!
=3
0)

o o

00

I

Figure 19. Infection of liver and heart by S. aureus Newman and variants.
Organ CFU counts comparing strain Newman with its single, double, and triple mutants. These
are pooled results from several trials, so N varies from strain to strain and are as follows:
Newman 30, Newman sspABCr.tc 20, Newman aurr.LacZ 20, Newman AaurSspABC 17,
Newman AaurSspABCScpAB 10, Newman sarAr.km 10, Newman AsarAsspABC 10.
** pO.001
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distribution of S. aureus within the organs by allowing the bacteria to spread invasively, though
this would need to be confirmed for consistency and qualitatively through histopathology. There
was no difference in overall virulence between Newman and any of its protease-deficient
variants in terms of weight loss.

3.12. USA300 and its sspABCr.tc mutant show differences in their distribution pattern in
mouse kidneys
In order to further elucidate any effect deletion of the proteases of the sspABC operon may have
on the colonization patterns or distribution of USA300 despite lack of difference in overall
virulence, kidneys of mice infected by USA300 or USA300 sspABCr.tc were fixed in formalin
and sectioned prior to Gram and H&E staining for bacterial and eukaryotic cells respectively. As
seen in Figure 20, histopathology samples comparing mouse kidney infected with USA300 and
USA300 sspABCr.tc show some differences in their distribution of bacteria. While USA300 wild
type forms abscesses within the kidney, it can also spread in a diffuse pattern that is not seen in
the sspABCr.tc mutant. A second difference is the observation that wild type USA300 will
infiltrate glomeruli while USA300 sspABCr.tc mainly occupies kidney tubules, suggesting that
the proteases of the sspABC operon may enable S. aureus to spread and invade host tissues more
effectively.

Figure 20. Histopathology analysis of kidneys infected with USA300 or USA300 sspABCr.tc.
Gram and H&E stains were applied to kidney cross sections of mice challenged with US A300 (A)
and USA300 sspABCwtc (B). Top two segments of each panel show Gram stain, and bottom two
segments of each panel show H&E staining. Right segments of each panel show a 200 x
magnification of boxed areas in the corresponding left segment.
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CHAPTER 4: DISCUSSION
As the role of staphylococcal biofilms in infectious disease is further elucidated, current
research has begun to focus on the polysaccharide independent method of biofilm formation
utilized by clinically relevant clones of methicillin-resistant S. aureus (O’Neill et al, 2007;
Lauderdale et al, 2009; Boles et al, 2010). Due to an up to six-fold increase in antibiotic
resistance of biofilm associated S. aureus (Boles and Horswill, 2008), staphylococcal biofilms
are notoriously difficult to eradicate, and the biofilm growth phenotype is heavily associated with
the persistence and chronic nature of biofilm-associated infections. Although initial work on
biofilm, especially in S. epidermidis, suggested that the biofilm mode of growth is heavily
dependent on its extracellular polysaccharide matrix (Kaplan et al, 2004), itJbecame evident that
the majority of S. aureus clinical isolates produce biofilm that is not affected by deletion of the
ica locus responsible for PNAG production (Beenken et al, 2004), but will be degraded by
proteolytic enzymes (O’Neill et al, 2007). Previous work has established that inactivation of
alternative a factor a inhibited biofilm growth due to an up-regulation of the RNAIII transcript
of agr. Further inactivation of the genes encoding Aur and the family of serine protease-like (Spl)
proteases restored biofilm growth, indicating that these proteases have a role in the proteolytic
dispersal of biofilms (Lauderdale et al, 2010). These inactivations, however, were largely formed
in the SHI000 background, a robust biofilm-forming laboratory strain that work in this thesis has
demonstrated to show minimal proteolytic activity (Fig 7), so the effect of extracellular proteases
on the growth phenotypes of this strain is innately low. Inactivation of the agr locus in the same
SHI 000 background produced a mutant strain that generated higher levels of biofilm, and again,
inactivation of the Aur and Spl proteases resulted in an increase in biofilm production under
conditions of high agr activity (Boles and Horswill, 2008). The AsigB and Aagr deletions have
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been transduced into CA-MRSA USA300 (Los Angeles County Clone), where the resulting
biofilm phenotype mirrored that of mutagenized SHI000 during flow cell biofilm growth
(Lauderdale et al, 2009). In another work, mutation of the sarA regulatory locus, the deletion of
which results in elevated exoprotease production, was found to decrease biofilm fomiing ability
in an osteomyelitis isolate UAMS-1, while agr mutation in this strain had little effect on its
biofilm forming capacity. Strain Newman, however, produced little biofilm under all conditions,
and laboratory strain RN6390, which is defective in c B activity, did not produce a notable
amount of biofilm unless its agr locus was deleted (Beenken et al, 2003). Together, this previous
work indicates that the factors controlling biofilm formation vary from strain to strain despite the
common theme of proteolytic activity leading to limited biofilm formation. It is important to note
that the range of genes affected by these regulatory mutations is extremely broad (Beenken et al,
2004), and little work has focussed on the biofilm-forming capacity of specific protease mutants
not subject to broad pleiotropic effects in a model strain of clinical importance that normally
expresses high levels of proteases. These series of proteases include those of the sspABC operon
of S. aureus, found to be highly expressed in hypervirulent CA-MRSA USA300 and rapidly
expressed upon phagocytic uptake (Burlak et al, 2007). This work therefore represents the first
demonstration of a role for sspABC in regulating biofilm growth using a clinically relevant and
highly virulent wild type strain of S', aureus.
In a popular model of biofilm growth, acidic pH is postulated to repress agr function,
thereby inhibiting production of secreted proteins, including proteases that might otherwise
promote biofilm dispersal (Yarwood et al, 2004). This drop in pH is the result of release of
glucose fermentation products into the bacterial growth environment, which include acetic acid
under aerobic growth conditions, and lactic acid during anaerobic growth (Regassa et al, 1992).

___________________________________________________________________________________________________
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Contrary to this prevailing hypothesis, this thesis has shown that glucose is necessary for optimal
production of secreted proteases, and moreover, that production of SspA is enhanced by
maintaining the culture at an acidic pH at which agr activity is thought to be limited.
Immunoblotting for Hla, which is de-repressed by RNAIII translationally, supported the claim
that agr activity is limited, since at low pH, Hla detection decreased. The fact that the same low
pH resulted in heightened SspA production as detected by immunoblot, as well as heightened
proteolytic activity as detected by FITC-liberation assays, strongly points to the presence of
further layers of regulation inherent in the production of proteases, most likely in the form of an
acid stress response system. While data in this thesis support the contention that agr activity is
repressed at acidic pHs, a closer and more specific study of the secreted proteases positively
regulated by this system has shown that agr repression is not the sole response to acidic
conditions. Though this thesis has demonstrated that deletion of the proteases of the sspABC
results in increased biofilm thickness and robustness, this increase is present at all pHs (Figure
10), including in acidic media, where production of the proteases is classically postulated to be
inhibited. The increase in biofilm formation in acidic conditions is therefore likely to be
correlated to other bacterial responses than repression of proteolytic activity. These responses
could include regulation of other biofilm associated proteins such as the S. aureus surface protein
G (SasG) found to be involved in polysaccharide independent biofilm formation (Corrigan et al,
2007; Tormo et al, 2007) or pH-dependent inhibition of enzymes such as nuclease that would
otherwise degrade matrix structural components such as eDNA (Rice et al, 2007). In the course
of the growth cycle of S. aureus, culture pH will dip and increase, and this change in pH in the
biofilm growth phenotype may be necessary for the completion of the biofilm growth cycle,
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leading to dispersal of the biofdm once pH rises enough to allow the activity of the various
factors that contribute to dispersal aside from proteases.
In the S. aureus growth cycle, fermentation products acetate and lactate are thought to
support a second round of bacterial growth after glucose in the growth medium is depleted,
leading to increased pH of the culture medium after the initial dip peaking at the end of
exponential growth (Somerville et al, 2003). The results of this thesis and a recent study by Rode
et al, 2010 confirm a decrease in culture pH concomitant with depletion of glucose and cessation
of exponential growth, as well as the support of further growth by lactic acid, leading to an
increase in pH during stationary phase. However, despite a similar initial decrease and later
increase in pH that occurs in media supplemented with acetic acid, there isdittle additional
growth that occurs, with the presence of acetic acid severely inhibiting the final culture density at
18 hours (Table 4). Both acetic acid and lactic acid are permeant small organic acids that can
restrict bacterial growth by acidification of the interior of S. aureus cells (Rode et al, 2010), but
the growth inhibition by acetic acid and not lactic acid suggests that while lactic acid is uptaken
and metabolized by the bacteria, acetic acid is depleted from the media through other means.
Acetic acid may be sequestered within bacterial cells or used for purposes other than metabolism,
such as acetylation of S. aureus peptidoglycan. Increasing concentrations of acetic acid resulted
in decreased production of SspA, most clearly seen when acetic acid supplementation was
performed in glucose-containing, pH 5.5-buffered media that encouraged high levels of protease
expression. This decrease of SspA may be effected directly through regulatory actions of acetic
acid, or it may be a result of the growth-inhibitory effect indirectly altering expression patterns.
The increase seen in SspA production as lactic acid was added to culture media suggests that
lactic acid can be used as a carbon source to support growth. Despite the growth inhibition that
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resulted from the addition of acetic acid, these data support a role for acetic acid in biofilm
formation. In addition to the induction of autolytic activity that releases bacterial eDNA into the
biofilm matrix as a structural component (Rice et al, 2007), the discovery that acetic acid
suppresses SspA production indicates that it may play a role in inhibition of biofilm dispersal in
a protease-mediated manner.
In both microplate and plastic cover slip biofilm growth assays, biofilm growth was
optimal at low pH, in the presence of glucose, and in the presence of a protein coat on the surface
of either microplate well or cover slip. This protein likely provides a point of attachment for
biofilm bacteria, and bovine serum albumin, human plasma, and bovine mucin were all effective
at increasing biofilm formation when used to coat the attachment surfaces..The sspABCv.tc
mutant of USA300 consistently outperformed wild type USA300 in biofilm growth, and this
effect was abrogated by complementation of the sspABC operon in trans. In microplate wells, the
protease-deficient mutant generated large clumps of bacteria adherent to the sides and bottom of
the biofilm wells that were visible to the human eye before and after staining with crystal violet
dye. Under scanning electron microscopy, the biofilm mat of USA300 sspABCv.tc was found to
be three times as thick in cross-section as that of wild type USA300, and the large clumps of
bacteria in the protease-deficient mutant were found to be towering communities of bacteria that
were over twice as tall as the thickest areas of biofilm mat. The proteases of the sspABC play a
role in dispersal of biofilm or in maintenance of an alternate composition or thickness of matrix,
leading to decreased thickness of biofilm mat and lack of large aggregations of bacteria in
communities in the biofilm growth phenotype of S. aureus.
In murine bacteraemia models, deletion of proteases of the sspABC operon in US A3 00,
or deletion of these and other major proteases in historical isolate Newman, resulted in no
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significant differences in overall virulence despite possible differences in bacterial distribution
throughout the mouse kidney that mirrors the enhanced clumping displayed by the protease-null
mutant in vitro. This is likely attributable to a subtle role played by the proteases in the virulence
strategy of S. aureus that is obfuscated in the complex interactions between host and pathogen
that occur in an in vivo model. Interestingly, historical strain Newman and its derivatives
produced higher cfu/organ counts in the infection model than emergent epidemic USA300,
especially in the spleen and the liver. Newman is characterized by heightened .smjRS activity as a
result of a single nucleotide polymorphism in the saeS gene, and this alters the virulence
expression pattern of Newman such that it produces high levels of adhesion and colonization
factors, but low levels of exotoxins and exoenzymes (Maniero et al, 2010; Novick and Jiang,
2003). Due to its shift in colonization versus invasion factors, Newman forms large clumps or
abscesses within the mouse organs, and this may be the cause of the increased cfu/organ count.
In terms of overall virulence, Newman did not cause more or less weight loss than USA300, so
its change in organ load is not more pathogenic, perhaps as a result of decreased exotoxin and
exoenzyme levels, which play a role in the triggering of an inflammatory response. When the
sspABC mutant of USA300 was complemented in trans with pRN5548::sspABC, the
complemented mutant showed a small but significant decrease in bacterial load in the livers of
infected mice. This may be a result of the overexpression of proteases in conjunction with the
high concentration of immune cells in the liver, which is meant to clean and filter blood. The
excessive production of proteases may cause elevated levels of inflammation, leading to more
recruitment of immune cells that would then act to clear the infection. As the major significant
differences in vitro between wild type strains and protease-null mutants have been in the biofilm
growth phenotype, a better in vivo model may result in elucidation of the pathophysiological
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roles of these proteases. The best model is potentially a biofilm growth model in which wild type
and protease-null mutants are introduced to common sites of biofilm deposition, such as
indwelling surgical devices, examples of which include catheters or stents. If the sspABC mutant
of USA300 shows heightened biofilm growth in vivo, the infection phenotype may show
increased virulence in the protease-null mutant, where the devices would become more readily
colonized and blocked, leading to increased inflammatory response and morbidity on the part of
the host animal. This and other models of biofilm growth infection represent interesting future
directions in elucidation of the role of the proteases of the sspABC operon in infectious disease
caused by S. aureus.
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